https://trial.medpath.com/news/drug-farm-secures-55-million-series-d-to-advance-ai-discovered-first-in-class-candidates-df-003-and-df-006 2026-07-13T12:12:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-farm-secures-55-million-series-d-to-advance-ai-discovered-first-in-class-candidates-df-003-and-df-006 2026-07-13T12:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/daily-cannabis-use-may-shift-the-brain-into-an-adapted-operating-state-new-research-suggests 2026-07-13T12:12:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daily-cannabis-use-may-shift-the-brain-into-an-adapted-operating-state-new-research-suggests 2026-07-13T12:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/global-consortium-c-brain-launches-open-source-ai-toolbox-to-tackle-alzheimer-s-99-drug-failure-rate 2026-07-13T12:11:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-consortium-c-brain-launches-open-source-ai-toolbox-to-tackle-alzheimer-s-99-drug-failure-rate 2026-07-13T12:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/thiogenesis-receives-fda-rare-pediatric-disease-designation-for-tti-0102-in-leigh-syndrome 2026-07-13T11:09:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thiogenesis-receives-fda-rare-pediatric-disease-designation-for-tti-0102-in-leigh-syndrome 2026-07-13T11:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/agenus-secures-up-to-340-million-to-advance-neoadjuvant-bot-bal-in-mss-colon-cancer-pivoting-away-from-metastatic-setting 2026-07-13T11:09:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agenus-secures-up-to-340-million-to-advance-neoadjuvant-bot-bal-in-mss-colon-cancer-pivoting-away-from-metastatic-setting 2026-07-13T11:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/sen-mitch-mcconnell-reveals-fall-led-to-hospitalization-cites-post-polio-condition-and-mild-pneumonia 2026-07-13T11:09:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sen-mitch-mcconnell-reveals-fall-led-to-hospitalization-cites-post-polio-condition-and-mild-pneumonia 2026-07-13T11:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/global-study-of-214000-older-adults-reveals-striking-country-specific-patterns-in-dementia-risk-factors 2026-07-13T11:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-study-of-214000-older-adults-reveals-striking-country-specific-patterns-in-dementia-risk-factors 2026-07-13T11:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/china-expands-personalized-cosmetic-service-pilot-to-23-provincial-level-regions 2026-07-13T11:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-expands-personalized-cosmetic-service-pilot-to-23-provincial-level-regions 2026-07-13T11:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/dynamic-single-cell-transcriptomic-analysis-reveals-immune-dysregulation-in-anti-nmdar-encephalitis 2026-07-13T10:12:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dynamic-single-cell-transcriptomic-analysis-reveals-immune-dysregulation-in-anti-nmdar-encephalitis 2026-07-13T10:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/eu-veterinary-vaccine-and-pharmacovigilance-training-courses-target-regulatory-gaps-under-regulation-2019-6 2026-07-13T10:12:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-veterinary-vaccine-and-pharmacovigilance-training-courses-target-regulatory-gaps-under-regulation-2019-6 2026-07-13T10:12:12+00:00 hourly 0.9 https://trial.medpath.com/news/uk-markey-cancer-center-and-lexington-clinic-renew-cancer-care-collaboration-through-2028 2026-07-13T10:11:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-markey-cancer-center-and-lexington-clinic-renew-cancer-care-collaboration-through-2028 2026-07-13T10:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/global-biotech-achieves-1-2-million-in-cloud-savings-through-sap-bw-optimization-with-capgemini 2026-07-13T10:11:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-biotech-achieves-1-2-million-in-cloud-savings-through-sap-bw-optimization-with-capgemini 2026-07-13T10:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/institute-of-cancer-research-staff-extend-historic-strike-over-pay-warn-of-existential-crisis 2026-07-13T10:10:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/institute-of-cancer-research-staff-extend-historic-strike-over-pay-warn-of-existential-crisis 2026-07-13T10:10:54+00:00 hourly 0.9 https://trial.medpath.com/news/charting-intratumor-heterogeneity-from-bench-to-bedside-a-comprehensive-review 2026-07-13T10:10:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/charting-intratumor-heterogeneity-from-bench-to-bedside-a-comprehensive-review 2026-07-13T10:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/genedrive-completes-paloh-uk-recruitment-nearly-6000-babies-tested-for-antibiotic-induced-hearing-loss-risk 2026-07-13T10:09:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genedrive-completes-paloh-uk-recruitment-nearly-6000-babies-tested-for-antibiotic-induced-hearing-loss-risk 2026-07-13T10:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-vaccines-remain-effective-despite-helminth-induced-immune-modulation-preclinical-study-shows 2026-07-13T08:10:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-19-vaccines-remain-effective-despite-helminth-induced-immune-modulation-preclinical-study-shows 2026-07-13T08:10:35+00:00 hourly 0.9 https://trial.medpath.com/news/faron-updates-bexmarilimab-iit-portfolio-blaze-switches-to-nivolumab-bexar-cleared-in-sarcoma-finprove-cohort-discontinued 2026-07-13T08:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faron-updates-bexmarilimab-iit-portfolio-blaze-switches-to-nivolumab-bexar-cleared-in-sarcoma-finprove-cohort-discontinued 2026-07-13T08:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/eu-pharmaceutical-reforms-reshape-rare-disease-and-pediatric-drug-development-strategies 2026-07-13T08:08:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-pharmaceutical-reforms-reshape-rare-disease-and-pediatric-drug-development-strategies 2026-07-13T08:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/qatar-s-hmc-launches-in-house-whole-exome-sequencing-expands-precision-medicine-with-20-million-annual-diagnostic-tests 2026-07-13T08:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qatar-s-hmc-launches-in-house-whole-exome-sequencing-expands-precision-medicine-with-20-million-annual-diagnostic-tests 2026-07-13T08:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/ondine-biomedical-s-lantern-phase-3-trial-meets-primary-endpoint-showing-40-reduction-in-surgical-site-infections 2026-07-13T07:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ondine-biomedical-s-lantern-phase-3-trial-meets-primary-endpoint-showing-40-reduction-in-surgical-site-infections 2026-07-13T07:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/scenesse-r-afamelanotide-approved-by-health-canada-for-erythropoietic-protoporphyria 2026-07-13T06:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scenesse-r-afamelanotide-approved-by-health-canada-for-erythropoietic-protoporphyria 2026-07-13T06:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/routine-eye-tests-lead-to-rare-uveal-melanoma-diagnoses-highlighting-access-gap-for-life-extending-chemosaturation-therapy-in-the-uk 2026-07-13T06:09:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/routine-eye-tests-lead-to-rare-uveal-melanoma-diagnoses-highlighting-access-gap-for-life-extending-chemosaturation-therapy-in-the-uk 2026-07-13T06:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/new-global-catalogue-of-239-human-infective-rna-viruses-identifies-pathogens-with-greatest-pandemic-potential 2026-07-13T06:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-global-catalogue-of-239-human-infective-rna-viruses-identifies-pathogens-with-greatest-pandemic-potential 2026-07-13T06:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/ihh-healthcare-and-fortis-announce-winners-of-inaugural-india-focused-healthcare-startup-accelerator 2026-07-13T05:09:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ihh-healthcare-and-fortis-announce-winners-of-inaugural-india-focused-healthcare-startup-accelerator 2026-07-13T05:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/over-half-of-gps-in-wales-say-they-routinely-cannot-meet-patient-demand-amid-severe-underinvestment 2026-07-13T05:09:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/over-half-of-gps-in-wales-say-they-routinely-cannot-meet-patient-demand-amid-severe-underinvestment 2026-07-13T05:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-panel-begins-review-to-loosen-restrictions-on-unapproved-peptides-amid-safety-concerns 2026-07-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-panel-begins-review-to-loosen-restrictions-on-unapproved-peptides-amid-safety-concerns 2026-07-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-to-convene-advisory-committee-to-review-sydnexis-s-syd-101-for-pediatric-progressive-myopia 2026-07-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-to-convene-advisory-committee-to-review-sydnexis-s-syd-101-for-pediatric-progressive-myopia 2026-07-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/low-uptake-of-cascade-germline-testing-in-cancer-represents-a-public-health-emergency-experts-warn 2026-07-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-uptake-of-cascade-germline-testing-in-cancer-represents-a-public-health-emergency-experts-warn 2026-07-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/addressing-social-inequalities-in-cancer-screening-uptake-among-underserved-populations 2026-07-12T21:21:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/addressing-social-inequalities-in-cancer-screening-uptake-among-underserved-populations 2026-07-12T21:21:28+00:00 hourly 0.9 https://trial.medpath.com/news/cultural-safety-in-healthcare-evidence-shows-it-saves-lives-amid-new-zealand-regulatory-overhaul 2026-07-12T21:20:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cultural-safety-in-healthcare-evidence-shows-it-saves-lives-amid-new-zealand-regulatory-overhaul 2026-07-12T21:20:20+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-upgraded-to-hold-amid-mixed-analyst-sentiment-and-stock-volatility 2026-07-12T20:11:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sana-biotechnology-upgraded-to-hold-amid-mixed-analyst-sentiment-and-stock-volatility 2026-07-12T20:11:33+00:00 hourly 0.9 https://trial.medpath.com/news/apogee-ceo-sells-20000-shares-under-pre-existing-trading-plan-as-zumilokibart-phase-3-looms 2026-07-12T20:11:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apogee-ceo-sells-20000-shares-under-pre-existing-trading-plan-as-zumilokibart-phase-3-looms 2026-07-12T20:11:28+00:00 hourly 0.9 https://trial.medpath.com/news/ucsf-consolidates-pediatric-bone-marrow-transplants-in-san-francisco-sparking-access-concerns-for-east-bay-families 2026-07-12T20:10:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucsf-consolidates-pediatric-bone-marrow-transplants-in-san-francisco-sparking-access-concerns-for-east-bay-families 2026-07-12T20:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/lifesci-capital-maintains-buy-rating-on-tenax-therapeutics-with-35-price-target 2026-07-12T19:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lifesci-capital-maintains-buy-rating-on-tenax-therapeutics-with-35-price-target 2026-07-12T19:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/tilray-medical-launches-eu-gmp-cbd100-oral-solution-in-panama-expanding-medical-cannabis-access-across-latin-america 2026-07-12T19:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tilray-medical-launches-eu-gmp-cbd100-oral-solution-in-panama-expanding-medical-cannabis-access-across-latin-america 2026-07-12T19:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/analysts-maintain-bullish-stance-on-insilico-medicine-with-price-targets-up-to-hk-77-50 2026-07-12T17:42:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/analysts-maintain-bullish-stance-on-insilico-medicine-with-price-targets-up-to-hk-77-50 2026-07-12T17:42:33+00:00 hourly 0.9 https://trial.medpath.com/news/thumbay-group-partners-with-geneva-college-of-longevity-science-to-launch-uae-s-first-academic-programs-in-longevity-medicine 2026-07-12T17:42:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thumbay-group-partners-with-geneva-college-of-longevity-science-to-launch-uae-s-first-academic-programs-in-longevity-medicine 2026-07-12T17:42:31+00:00 hourly 0.9 https://trial.medpath.com/news/hdt-bio-launches-canadian-phase-1-trial-of-hdt-401-a-locally-administered-rna-immune-activator-for-glioblastoma 2026-07-12T17:42:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hdt-bio-launches-canadian-phase-1-trial-of-hdt-401-a-locally-administered-rna-immune-activator-for-glioblastoma 2026-07-12T17:42:11+00:00 hourly 0.9 https://trial.medpath.com/news/prioritizing-women-s-brain-health-can-save-lives-and-global-economies-leading-alzheimer-s-organizations-warn 2026-07-12T17:41:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prioritizing-women-s-brain-health-can-save-lives-and-global-economies-leading-alzheimer-s-organizations-warn 2026-07-12T17:41:41+00:00 hourly 0.9 https://trial.medpath.com/news/princess-of-wales-praises-wimbledon-finalist-continuing-to-compete-through-breast-cancer-treatment 2026-07-12T17:41:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/princess-of-wales-praises-wimbledon-finalist-continuing-to-compete-through-breast-cancer-treatment 2026-07-12T17:41:20+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-gain-traction-among-public-figures-for-weight-management-and-cardiometabolic-health 2026-07-12T17:39:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-gain-traction-among-public-figures-for-weight-management-and-cardiometabolic-health 2026-07-12T17:39:56+00:00 hourly 0.9 https://trial.medpath.com/news/brexit-blocks-uk-children-from-accessing-life-extending-drug-trial-for-aggressive-brain-cancer 2026-07-12T15:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brexit-blocks-uk-children-from-accessing-life-extending-drug-trial-for-aggressive-brain-cancer 2026-07-12T15:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/growing-concern-over-opioid-abuse-and-addiction-among-sickle-cell-disease-patients-in-nigeria 2026-07-12T15:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/growing-concern-over-opioid-abuse-and-addiction-among-sickle-cell-disease-patients-in-nigeria 2026-07-12T15:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/gum-disease-bacterium-p-gingivalis-linked-to-heart-valve-calcification-via-il-1b-pathway 2026-07-12T15:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gum-disease-bacterium-p-gingivalis-linked-to-heart-valve-calcification-via-il-1b-pathway 2026-07-12T15:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/hemab-therapeutics-unveils-hmb-002-proof-of-mechanism-data-in-vwd-and-announces-novel-antifibrinolytic-hmb-003-at-isth-2026 2026-07-12T15:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemab-therapeutics-unveils-hmb-002-proof-of-mechanism-data-in-vwd-and-announces-novel-antifibrinolytic-hmb-003-at-isth-2026 2026-07-12T15:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/evaxion-unveils-preclinical-data-for-ai-designed-cmv-vaccine-candidate-evx-v1-featuring-novel-antigens 2026-07-12T15:07:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evaxion-unveils-preclinical-data-for-ai-designed-cmv-vaccine-candidate-evx-v1-featuring-novel-antigens 2026-07-12T15:07:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-crispr-therapeutics-casgevy-for-pediatric-use-expanding-gene-editing-market-potential 2026-07-12T11:06:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-crispr-therapeutics-casgevy-for-pediatric-use-expanding-gene-editing-market-potential 2026-07-12T11:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/maharashtra-fda-bars-sale-of-two-cadila-drugs-over-brand-confusion-seizes-rs-2-45-crore-stock 2026-07-12T10:07:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maharashtra-fda-bars-sale-of-two-cadila-drugs-over-brand-confusion-seizes-rs-2-45-crore-stock 2026-07-12T10:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clearance-of-qiastat-dx-bloodstream-panel-marks-a-potential-turnaround-for-qiagen-s-syndromic-testing-franchise 2026-07-12T10:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clearance-of-qiastat-dx-bloodstream-panel-marks-a-potential-turnaround-for-qiagen-s-syndromic-testing-franchise 2026-07-12T10:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/feeder-free-til-expansion-platform-reduces-il-2-dependence-and-enhances-anti-tumor-efficacy-in-preclinical-study 2026-07-12T08:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/feeder-free-til-expansion-platform-reduces-il-2-dependence-and-enhances-anti-tumor-efficacy-in-preclinical-study 2026-07-12T08:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/beta-technologies-completes-first-evtol-flights-in-us-government-pilot-program-transporting-manufactured-organs-for-united-therapeutics 2026-07-12T07:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beta-technologies-completes-first-evtol-flights-in-us-government-pilot-program-transporting-manufactured-organs-for-united-therapeutics 2026-07-12T07:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/yale-scientists-identify-two-membrane-proteins-that-drive-parkinson-s-disease-spread-through-the-brain 2026-07-12T05:09:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-scientists-identify-two-membrane-proteins-that-drive-parkinson-s-disease-spread-through-the-brain 2026-07-12T05:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/insurance-supported-integrative-oncology-program-delivers-clinically-meaningful-symptom-relief-for-cancer-patients 2026-07-12T05:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insurance-supported-integrative-oncology-program-delivers-clinically-meaningful-symptom-relief-for-cancer-patients 2026-07-12T05:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-sanofi-s-sarclisa-subcutaneous-formulation-offering-new-dosing-option-for-multiple-myeloma 2026-07-12T05:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-sanofi-s-sarclisa-subcutaneous-formulation-offering-new-dosing-option-for-multiple-myeloma 2026-07-12T05:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/psilocybin-therapy-shows-promise-for-anorexia-nervosa-in-early-stage-trial 2026-07-12T05:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psilocybin-therapy-shows-promise-for-anorexia-nervosa-in-early-stage-trial 2026-07-12T05:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/cafc-affirms-107-5-million-patent-invalidation-enablement-gaps-in-wyeth-s-egfr-inhibitor-dosing-claims 2026-07-12T04:09:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cafc-affirms-107-5-million-patent-invalidation-enablement-gaps-in-wyeth-s-egfr-inhibitor-dosing-claims 2026-07-12T04:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/the-iron-lung-is-gone-polio-isn-t-experts-warn-against-complacency-as-last-american-iron-lung-user-dies-at-78 2026-07-12T03:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-iron-lung-is-gone-polio-isn-t-experts-warn-against-complacency-as-last-american-iron-lung-user-dies-at-78 2026-07-12T03:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/reed-jobs-yosemite-targets-350m-second-fund-as-ai-collides-with-cancer-drug-discovery 2026-07-12T02:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reed-jobs-yosemite-targets-350m-second-fund-as-ai-collides-with-cancer-drug-discovery 2026-07-12T02:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/bacteria-use-hydrogel-powered-escape-pods-to-survive-opening-new-avenues-against-antibiotic-resistant-biofilms 2026-07-12T02:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bacteria-use-hydrogel-powered-escape-pods-to-survive-opening-new-avenues-against-antibiotic-resistant-biofilms 2026-07-12T02:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/glucose-and-hba1c-mediate-obesity-pancreatic-cancer-link-uk-biobank-study-finds 2026-07-12T01:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glucose-and-hba1c-mediate-obesity-pancreatic-cancer-link-uk-biobank-study-finds 2026-07-12T01:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/non-invasive-brain-stimulation-significantly-improves-depression-in-just-10-days-placebo-controlled-trial-finds 2026-07-12T01:06:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/non-invasive-brain-stimulation-significantly-improves-depression-in-just-10-days-placebo-controlled-trial-finds 2026-07-12T01:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/former-mayo-clinic-director-alleges-ai-research-misconduct-data-manipulation-and-retaliation-in-federal-lawsuit 2026-07-12T01:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-mayo-clinic-director-alleges-ai-research-misconduct-data-manipulation-and-retaliation-in-federal-lawsuit 2026-07-12T01:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/holy-see-calls-for-renewed-global-commitment-to-end-aids-warns-children-remain-disproportionately-vulnerable 2026-07-11T23:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/holy-see-calls-for-renewed-global-commitment-to-end-aids-warns-children-remain-disproportionately-vulnerable 2026-07-11T23:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/financial-headwinds-mount-for-milestone-and-mirum-pharmaceuticals-as-both-burn-through-cash 2026-07-11T23:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/financial-headwinds-mount-for-milestone-and-mirum-pharmaceuticals-as-both-burn-through-cash 2026-07-11T23:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-launches-first-long-term-prescription-drug-drone-delivery-program-by-a-u-s-health-system 2026-07-11T23:08:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-launches-first-long-term-prescription-drug-drone-delivery-program-by-a-u-s-health-system 2026-07-11T23:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/cruise-ship-ultrafine-particles-promote-inflammation-and-viral-replication-study-finds 2026-07-11T23:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cruise-ship-ultrafine-particles-promote-inflammation-and-viral-replication-study-finds 2026-07-11T23:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/point-of-care-car-t-manufacturing-achieves-15-day-vein-to-vein-time-in-jordan-phase-ii-trial 2026-07-11T23:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/point-of-care-car-t-manufacturing-achieves-15-day-vein-to-vein-time-in-jordan-phase-ii-trial 2026-07-11T23:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/study-links-oxalate-to-systemic-inflammation-and-heart-damage-via-il-17a-pathway-in-kidney-disease 2026-07-11T22:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-links-oxalate-to-systemic-inflammation-and-heart-damage-via-il-17a-pathway-in-kidney-disease 2026-07-11T22:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/medical-ai-ecosystem-innovation-forum-highlights-data-driven-transformation-in-healthcare-and-drug-discovery 2026-07-11T22:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medical-ai-ecosystem-innovation-forum-highlights-data-driven-transformation-in-healthcare-and-drug-discovery 2026-07-11T22:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-efimosfermin-opens-two-phase-3-trials-targeting-mash-cirrhosis-signaling-a-shift-toward-disease-modifying-outcomes 2026-07-11T21:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-efimosfermin-opens-two-phase-3-trials-targeting-mash-cirrhosis-signaling-a-shift-toward-disease-modifying-outcomes 2026-07-11T21:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/kmt2-mutations-predict-immunotherapy-benefit-in-esophageal-adenocarcinoma-not-squamous-cell-carcinoma 2026-07-11T21:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kmt2-mutations-predict-immunotherapy-benefit-in-esophageal-adenocarcinoma-not-squamous-cell-carcinoma 2026-07-11T21:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/bruce-power-wins-regulatory-approval-to-process-cancer-fighting-lutetium-177-on-site 2026-07-11T21:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bruce-power-wins-regulatory-approval-to-process-cancer-fighting-lutetium-177-on-site 2026-07-11T21:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/tp53-mutation-drives-cd8-t-cell-exhaustion-and-therapy-resistance-in-urothelial-carcinoma 2026-07-11T21:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tp53-mutation-drives-cd8-t-cell-exhaustion-and-therapy-resistance-in-urothelial-carcinoma 2026-07-11T21:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/focused-ultrasound-foundation-launches-five-preclinical-projects-targeting-glioblastoma-liver-cancer-and-breast-cancer 2026-07-11T20:10:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/focused-ultrasound-foundation-launches-five-preclinical-projects-targeting-glioblastoma-liver-cancer-and-breast-cancer 2026-07-11T20:10:44+00:00 hourly 0.9 https://trial.medpath.com/news/dietary-intervention-reduces-bmi-regardless-of-genetic-obesity-risk-clinical-trial-finds 2026-07-11T20:10:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dietary-intervention-reduces-bmi-regardless-of-genetic-obesity-risk-clinical-trial-finds 2026-07-11T20:10:20+00:00 hourly 0.9 https://trial.medpath.com/news/san-francisco-mayor-signs-legislation-expanding-drug-free-supportive-housing-to-combat-overdose-crisis 2026-07-11T20:10:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/san-francisco-mayor-signs-legislation-expanding-drug-free-supportive-housing-to-combat-overdose-crisis 2026-07-11T20:10:12+00:00 hourly 0.9 https://trial.medpath.com/news/insurance-denials-for-brand-name-drugs-surge-67-over-six-years-jama-study-finds 2026-07-11T19:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insurance-denials-for-brand-name-drugs-surge-67-over-six-years-jama-study-finds 2026-07-11T19:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/federal-grants-expand-street-medicine-training-to-bring-care-directly-to-people-experiencing-homelessness 2026-07-11T19:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-grants-expand-street-medicine-training-to-bring-care-directly-to-people-experiencing-homelessness 2026-07-11T19:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/mohs-surgery-demonstrates-97-99-cure-rates-in-select-early-stage-melanoma-with-real-time-margin-control 2026-07-11T18:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mohs-surgery-demonstrates-97-99-cure-rates-in-select-early-stage-melanoma-with-real-time-margin-control 2026-07-11T18:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/im-ms-irradiation-reduces-breast-cancer-mortality-but-fails-to-improve-overall-survival-in-node-negative-disease-20-year-eortc-analysis 2026-07-11T17:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/im-ms-irradiation-reduces-breast-cancer-mortality-but-fails-to-improve-overall-survival-in-node-negative-disease-20-year-eortc-analysis 2026-07-11T17:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/emcure-subsidiary-gennova-divests-mrna-business-to-immunoscript-for-139-crore-to-refocus-on-biosimilars 2026-07-11T17:09:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emcure-subsidiary-gennova-divests-mrna-business-to-immunoscript-for-139-crore-to-refocus-on-biosimilars 2026-07-11T17:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-achieves-complete-remission-in-pregnant-patient-with-stage-iv-melanoma-brain-metastasis 2026-07-11T17:09:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-achieves-complete-remission-in-pregnant-patient-with-stage-iv-melanoma-brain-metastasis 2026-07-11T17:09:17+00:00 hourly 0.9 https://trial.medpath.com/news/cu-anschutz-launches-phase-2-trial-of-cbd-formulation-for-restless-legs-syndrome 2026-07-11T17:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cu-anschutz-launches-phase-2-trial-of-cbd-formulation-for-restless-legs-syndrome 2026-07-11T17:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/ibri-to-host-inaugural-2026-global-forum-on-science-philanthropy-and-investment 2026-07-11T17:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibri-to-host-inaugural-2026-global-forum-on-science-philanthropy-and-investment 2026-07-11T17:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/california-awards-1-8-million-to-launch-next-generation-precision-medicine-research-program 2026-07-11T17:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/california-awards-1-8-million-to-launch-next-generation-precision-medicine-research-program 2026-07-11T17:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/ed-expands-kerala-organ-trafficking-probe-summons-senior-doctors-from-transplant-evaluation-committees 2026-07-11T17:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ed-expands-kerala-organ-trafficking-probe-summons-senior-doctors-from-transplant-evaluation-committees 2026-07-11T17:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/fermented-foods-gain-scientific-and-regulatory-traction-as-gut-health-takes-center-stage 2026-07-11T12:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fermented-foods-gain-scientific-and-regulatory-traction-as-gut-health-takes-center-stage 2026-07-11T12:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/single-nucleus-transcriptomics-based-drug-screening-platform-identifies-candidate-compounds-for-focal-cortical-dysplasia 2026-07-11T11:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-nucleus-transcriptomics-based-drug-screening-platform-identifies-candidate-compounds-for-focal-cortical-dysplasia 2026-07-11T11:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/tel-aviv-researchers-identify-hidden-regenerative-cell-population-in-the-inner-ear-opening-new-path-to-hearing-restoration 2026-07-11T10:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tel-aviv-researchers-identify-hidden-regenerative-cell-population-in-the-inner-ear-opening-new-path-to-hearing-restoration 2026-07-11T10:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/former-ny-nurse-practitioner-hit-with-record-544000-penalty-for-falsifying-162-children-s-vaccination-records 2026-07-11T07:07:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-ny-nurse-practitioner-hit-with-record-544000-penalty-for-falsifying-162-children-s-vaccination-records 2026-07-11T07:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-off-the-shelf-t-cell-therapy-achieves-56-8-response-rate-in-rare-often-fatal-brain-infection 2026-07-11T06:09:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-off-the-shelf-t-cell-therapy-achieves-56-8-response-rate-in-rare-often-fatal-brain-infection 2026-07-11T06:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/scale-up-not-lab-results-is-now-the-binding-constraint-on-synthetic-biology-s-commercial-future 2026-07-11T06:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scale-up-not-lab-results-is-now-the-binding-constraint-on-synthetic-biology-s-commercial-future 2026-07-11T06:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-proposes-rule-to-streamline-distributed-manufacturing-registration-and-close-foreign-api-supply-chain-gaps 2026-07-11T06:08:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-proposes-rule-to-streamline-distributed-manufacturing-registration-and-close-foreign-api-supply-chain-gaps 2026-07-11T06:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/chryscapital-led-consortium-acquires-controlling-stake-in-novartis-india-via-off-market-transfer 2026-07-11T05:07:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chryscapital-led-consortium-acquires-controlling-stake-in-novartis-india-via-off-market-transfer 2026-07-11T05:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/dietary-supplement-regulation-what-the-2026-listing-bill-would-and-would-not-change 2026-07-11T04:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dietary-supplement-regulation-what-the-2026-listing-bill-would-and-would-not-change 2026-07-11T04:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/judicial-delay-in-landmark-ribociclib-access-case-petitioner-dies-as-kerala-high-court-lists-matter-57-times-without-final-hearing 2026-07-11T03:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/judicial-delay-in-landmark-ribociclib-access-case-petitioner-dies-as-kerala-high-court-lists-matter-57-times-without-final-hearing 2026-07-11T03:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/hearing-loss-affects-1-in-4-adults-with-type-2-diabetes-systematic-review-reveals 2026-07-11T01:14:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hearing-loss-affects-1-in-4-adults-with-type-2-diabetes-systematic-review-reveals 2026-07-11T01:14:33+00:00 hourly 0.9 https://trial.medpath.com/news/pygo2-identified-as-key-driver-of-1q21-multiple-myeloma-progression-and-potential-therapeutic-target 2026-07-11T01:14:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pygo2-identified-as-key-driver-of-1q21-multiple-myeloma-progression-and-potential-therapeutic-target 2026-07-11T01:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/countable-labs-and-promega-forge-co-marketing-agreement-to-streamline-rare-variant-detection-with-single-molecule-pcr 2026-07-11T01:14:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/countable-labs-and-promega-forge-co-marketing-agreement-to-streamline-rare-variant-detection-with-single-molecule-pcr 2026-07-11T01:14:04+00:00 hourly 0.9 https://trial.medpath.com/news/children-s-wisconsin-becomes-first-u-s-hospital-to-administer-avlayah-a-blood-brain-barrier-crossing-enzyme-replacement-therapy-for-hunter-syndrome 2026-07-11T00:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/children-s-wisconsin-becomes-first-u-s-hospital-to-administer-avlayah-a-blood-brain-barrier-crossing-enzyme-replacement-therapy-for-hunter-syndrome 2026-07-11T00:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-to-participate-in-b-riley-securities-2026-mind-muscle-vision-summit 2026-07-10T22:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanda-pharmaceuticals-to-participate-in-b-riley-securities-2026-mind-muscle-vision-summit 2026-07-10T22:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/uva-health-becomes-first-in-virginia-to-offer-hepzato-for-uveal-melanoma-with-liver-metastases 2026-07-10T21:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uva-health-becomes-first-in-virginia-to-offer-hepzato-for-uveal-melanoma-with-liver-metastases 2026-07-10T21:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/federal-340b-drug-discount-program-saves-uc-davis-health-289-million-expands-patient-access-to-vital-medications 2026-07-10T21:11:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-340b-drug-discount-program-saves-uc-davis-health-289-million-expands-patient-access-to-vital-medications 2026-07-10T21:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/targeting-neuroinflammation-in-spinal-cord-injury-from-inflammatory-mechanisms-to-pharmacological-interventions 2026-07-10T21:10:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeting-neuroinflammation-in-spinal-cord-injury-from-inflammatory-mechanisms-to-pharmacological-interventions 2026-07-10T21:10:42+00:00 hourly 0.9 https://trial.medpath.com/news/state-medical-boards-say-ai-is-not-ready-for-independent-licensure-urge-physician-accountability 2026-07-10T21:10:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/state-medical-boards-say-ai-is-not-ready-for-independent-licensure-urge-physician-accountability 2026-07-10T21:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-rally-poised-to-continue-as-innovation-obesity-market-and-m-a-drive-sector-momentum 2026-07-10T21:10:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-rally-poised-to-continue-as-innovation-obesity-market-and-m-a-drive-sector-momentum 2026-07-10T21:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/trump-nominee-for-hhs-preparedness-role-questioned-vaccine-safety-raising-confirmation-clash 2026-07-10T21:10:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-nominee-for-hhs-preparedness-role-questioned-vaccine-safety-raising-confirmation-clash 2026-07-10T21:10:12+00:00 hourly 0.9 https://trial.medpath.com/news/google-s-sensorfm-a-trillion-minute-foundation-model-that-rivals-clinical-lab-tests-for-wearable-health-ai 2026-07-10T21:10:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/google-s-sensorfm-a-trillion-minute-foundation-model-that-rivals-clinical-lab-tests-for-wearable-health-ai 2026-07-10T21:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/the-primary-care-crisis-paradox-medpac-data-challenges-prevailing-narrative-on-u-s-healthcare-reform 2026-07-10T20:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-primary-care-crisis-paradox-medpac-data-challenges-prevailing-narrative-on-u-s-healthcare-reform 2026-07-10T20:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/rural-radiation-oncology-clinic-closures-threaten-cancer-patient-care-across-the-u-s 2026-07-10T19:15:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rural-radiation-oncology-clinic-closures-threaten-cancer-patient-care-across-the-u-s 2026-07-10T19:15:42+00:00 hourly 0.9 https://trial.medpath.com/news/maia-biotechnology-advances-site-specific-radioimmunoconjugate-platform-as-insiders-and-analysts-signal-confidence 2026-07-10T19:15:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maia-biotechnology-advances-site-specific-radioimmunoconjugate-platform-as-insiders-and-analysts-signal-confidence 2026-07-10T19:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/eosinophil-diversity-unveiled-single-cell-atlas-reveals-distinct-subtypes-and-novel-therapeutic-targets 2026-07-10T19:15:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eosinophil-diversity-unveiled-single-cell-atlas-reveals-distinct-subtypes-and-novel-therapeutic-targets 2026-07-10T19:15:25+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-to-cut-up-to-130-jobs-in-basel-as-it-discontinues-small-scale-biologics-production 2026-07-10T19:15:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-to-cut-up-to-130-jobs-in-basel-as-it-discontinues-small-scale-biologics-production 2026-07-10T19:15:24+00:00 hourly 0.9 https://trial.medpath.com/news/warburg-pincus-nears-7-billion-acquisition-of-rare-disease-specialty-pharmacy-pantherx-rare 2026-07-10T19:15:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/warburg-pincus-nears-7-billion-acquisition-of-rare-disease-specialty-pharmacy-pantherx-rare 2026-07-10T19:15:22+00:00 hourly 0.9 https://trial.medpath.com/news/precise-consortium-launches-to-build-predictive-cancer-vulnerability-maps-across-europe 2026-07-10T18:12:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precise-consortium-launches-to-build-predictive-cancer-vulnerability-maps-across-europe 2026-07-10T18:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/blue-led-light-and-textbook-chemistry-enable-two-for-one-carbon-modification-accelerating-complex-drug-synthesis 2026-07-10T18:12:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blue-led-light-and-textbook-chemistry-enable-two-for-one-carbon-modification-accelerating-complex-drug-synthesis 2026-07-10T18:12:12+00:00 hourly 0.9 https://trial.medpath.com/news/wvu-and-johns-hopkins-launch-rural-health-research-series-with-focus-on-social-prescribing-and-cardiovascular-health-in-pregnancy 2026-07-10T18:12:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wvu-and-johns-hopkins-launch-rural-health-research-series-with-focus-on-social-prescribing-and-cardiovascular-health-in-pregnancy 2026-07-10T18:12:11+00:00 hourly 0.9 https://trial.medpath.com/news/trimaster-crossover-trial-shows-routine-clinical-data-may-outperform-diabetes-subtypes-for-precision-prescribing 2026-07-10T18:10:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trimaster-crossover-trial-shows-routine-clinical-data-may-outperform-diabetes-subtypes-for-precision-prescribing 2026-07-10T18:10:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-elevar-s-rivoceranib-camrelizumab-combination-in-first-line-hcc 2026-07-10T18:10:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-for-elevar-s-rivoceranib-camrelizumab-combination-in-first-line-hcc 2026-07-10T18:10:48+00:00 hourly 0.9 https://trial.medpath.com/news/niche-targeted-yap-taz-activation-offers-new-paradigm-for-bone-marrow-regeneration-after-myeloablative-therapy 2026-07-10T18:10:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/niche-targeted-yap-taz-activation-offers-new-paradigm-for-bone-marrow-regeneration-after-myeloablative-therapy 2026-07-10T18:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-medications-in-adolescents-balancing-early-obesity-treatment-against-unanswered-long-term-questions 2026-07-10T18:10:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-medications-in-adolescents-balancing-early-obesity-treatment-against-unanswered-long-term-questions 2026-07-10T18:10:39+00:00 hourly 0.9 https://trial.medpath.com/news/winn-clinical-investigator-pathway-program-launches-fifth-cohort-to-diversify-the-clinical-trial-workforce 2026-07-10T18:10:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/winn-clinical-investigator-pathway-program-launches-fifth-cohort-to-diversify-the-clinical-trial-workforce 2026-07-10T18:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/asco-publishes-first-ever-guideline-on-ctdna-testing-in-solid-tumors-and-lymphoma 2026-07-10T18:09:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asco-publishes-first-ever-guideline-on-ctdna-testing-in-solid-tumors-and-lymphoma 2026-07-10T18:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-identify-microrna-signatures-that-predict-stem-cell-therapy-response-in-knee-osteoarthritis 2026-07-10T16:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-identify-microrna-signatures-that-predict-stem-cell-therapy-response-in-knee-osteoarthritis 2026-07-10T16:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-staffing-crisis-and-policy-chaos-threaten-u-s-biomedical-innovation-leadership-congressional-hearing-reveals 2026-07-10T16:13:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-staffing-crisis-and-policy-chaos-threaten-u-s-biomedical-innovation-leadership-congressional-hearing-reveals 2026-07-10T16:13:33+00:00 hourly 0.9 https://trial.medpath.com/news/longevity-industry-moves-to-establish-its-own-regulatory-framework 2026-07-10T16:13:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longevity-industry-moves-to-establish-its-own-regulatory-framework 2026-07-10T16:13:24+00:00 hourly 0.9 https://trial.medpath.com/news/senate-review-scrutinizes-federal-handling-of-covid-19-vaccine-safety-signals-through-vaers 2026-07-10T16:12:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-review-scrutinizes-federal-handling-of-covid-19-vaccine-safety-signals-through-vaers 2026-07-10T16:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-histology-biomarker-predicts-aggressiveness-in-muscle-invasive-bladder-cancer 2026-07-10T16:11:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-histology-biomarker-predicts-aggressiveness-in-muscle-invasive-bladder-cancer 2026-07-10T16:11:59+00:00 hourly 0.9 https://trial.medpath.com/news/one-in-five-u-s-workers-tested-positive-on-hair-drug-tests-in-2025-while-fentanyl-positivity-fell-by-nearly-half 2026-07-10T16:11:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/one-in-five-u-s-workers-tested-positive-on-hair-drug-tests-in-2025-while-fentanyl-positivity-fell-by-nearly-half 2026-07-10T16:11:27+00:00 hourly 0.9 https://trial.medpath.com/news/greenland-mines-secures-australian-patent-for-klotho-based-gene-therapy-targeting-als-and-neuromuscular-diseases 2026-07-10T16:11:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greenland-mines-secures-australian-patent-for-klotho-based-gene-therapy-targeting-als-and-neuromuscular-diseases 2026-07-10T16:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/vmd-launches-digital-pharmacovigilance-reporting-platform-for-animal-medicines-industry 2026-07-10T16:10:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vmd-launches-digital-pharmacovigilance-reporting-platform-for-animal-medicines-industry 2026-07-10T16:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/probiotic-micro-pellets-market-poised-to-reach-1-1-billion-by-2036-on-11-3-cagr 2026-07-10T16:10:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/probiotic-micro-pellets-market-poised-to-reach-1-1-billion-by-2036-on-11-3-cagr 2026-07-10T16:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/un-women-reports-1-million-women-and-girls-cut-off-from-life-saving-aid-amid-global-funding-crisis 2026-07-10T16:10:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/un-women-reports-1-million-women-and-girls-cut-off-from-life-saving-aid-amid-global-funding-crisis 2026-07-10T16:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/phelan-mcdermid-syndrome-prevalence-estimated-at-1-in-7300-far-higher-than-previously-thought 2026-07-10T14:17:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phelan-mcdermid-syndrome-prevalence-estimated-at-1-in-7300-far-higher-than-previously-thought 2026-07-10T14:17:52+00:00 hourly 0.9 https://trial.medpath.com/news/ifebemtinib-plus-garsorasib-shows-82-orr-and-22-month-pfs-in-first-line-kras-g12c-mutant-nsclc 2026-07-10T12:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ifebemtinib-plus-garsorasib-shows-82-orr-and-22-month-pfs-in-first-line-kras-g12c-mutant-nsclc 2026-07-10T12:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/automated-liquid-handling-technologies-market-to-reach-us-7-4-billion-by-2034-driven-by-ai-integration-and-drug-discovery-demand 2026-07-10T12:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/automated-liquid-handling-technologies-market-to-reach-us-7-4-billion-by-2034-driven-by-ai-integration-and-drug-discovery-demand 2026-07-10T12:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-lomb-halts-glaucoma-program-for-bl1107-eye-drops-after-phase-2-miss-shifts-focus-to-geographic-atrophy-implant 2026-07-10T11:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bausch-lomb-halts-glaucoma-program-for-bl1107-eye-drops-after-phase-2-miss-shifts-focus-to-geographic-atrophy-implant 2026-07-10T11:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-builds-momentum-with-positive-teton-1-data-in-ipf-and-pipeline-expansion 2026-07-10T08:09:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-therapeutics-builds-momentum-with-positive-teton-1-data-in-ipf-and-pipeline-expansion 2026-07-10T08:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/jiva-pharma-ceo-om-prakash-goel-honored-by-marquis-who-s-who-for-six-decades-of-drug-discovery-innovation 2026-07-10T08:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jiva-pharma-ceo-om-prakash-goel-honored-by-marquis-who-s-who-for-six-decades-of-drug-discovery-innovation 2026-07-10T08:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-and-medtech-industry-agree-on-mdufa-vi-draft-commitment-letter-with-faster-pre-submission-pathway-and-enhanced-performance-goals 2026-07-10T08:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-and-medtech-industry-agree-on-mdufa-vi-draft-commitment-letter-with-faster-pre-submission-pathway-and-enhanced-performance-goals 2026-07-10T08:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-study-shows-hifu-is-safe-and-promising-for-treating-twin-to-twin-transfusion-syndrome 2026-07-10T08:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-first-study-shows-hifu-is-safe-and-promising-for-treating-twin-to-twin-transfusion-syndrome 2026-07-10T08:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/ovid-therapeutics-reshapes-executive-leadership-to-drive-next-phase-of-cns-pipeline-development 2026-07-10T07:07:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ovid-therapeutics-reshapes-executive-leadership-to-drive-next-phase-of-cns-pipeline-development 2026-07-10T07:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/frog-gut-bacterium-ewingella-americana-achieves-100-tumor-elimination-in-mice-with-a-single-dose 2026-07-10T06:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/frog-gut-bacterium-ewingella-americana-achieves-100-tumor-elimination-in-mice-with-a-single-dose 2026-07-10T06:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/fasting-activates-gut-microbe-akk-to-prime-intestinal-repair-after-radiation-injury 2026-07-10T06:07:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fasting-activates-gut-microbe-akk-to-prime-intestinal-repair-after-radiation-injury 2026-07-10T06:07:53+00:00 hourly 0.9 https://trial.medpath.com/news/hlb-s-liver-cancer-drug-rivoceranib-hits-third-fda-setback-over-manufacturing-compliance-issues 2026-07-10T06:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hlb-s-liver-cancer-drug-rivoceranib-hits-third-fda-setback-over-manufacturing-compliance-issues 2026-07-10T06:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/rural-healthcare-must-move-beyond-hospitals-ai-first-care-models-and-structural-transformation-needed 2026-07-10T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rural-healthcare-must-move-beyond-hospitals-ai-first-care-models-and-structural-transformation-needed 2026-07-10T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/antitrust-battle-over-enbrel-monopoly-escalates-as-amici-clash-in-fourth-circuit-appeals 2026-07-10T03:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antitrust-battle-over-enbrel-monopoly-escalates-as-amici-clash-in-fourth-circuit-appeals 2026-07-10T03:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/hillsboro-medical-center-to-close-one-of-oregon-s-three-geriatric-psychiatry-units-amid-staffing-crisis 2026-07-10T03:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hillsboro-medical-center-to-close-one-of-oregon-s-three-geriatric-psychiatry-units-amid-staffing-crisis 2026-07-10T03:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/katalin-kariko-traces-mrna-journey-from-discovery-to-therapeutic-revolution-at-75th-lindau-nobel-laureate-meeting 2026-07-10T03:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/katalin-kariko-traces-mrna-journey-from-discovery-to-therapeutic-revolution-at-75th-lindau-nobel-laureate-meeting 2026-07-10T03:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/first-line-ici-combinations-show-encouraging-response-but-no-definitive-survival-benefit-in-advanced-pancreatic-cancer 2026-07-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-line-ici-combinations-show-encouraging-response-but-no-definitive-survival-benefit-in-advanced-pancreatic-cancer 2026-07-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dengue-cases-surge-to-record-14-6-million-in-2024-as-climate-change-drives-mosquito-borne-diseases-into-new-regions 2026-07-09T23:09:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dengue-cases-surge-to-record-14-6-million-in-2024-as-climate-change-drives-mosquito-borne-diseases-into-new-regions 2026-07-09T23:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/spatial-proteomics-market-poised-to-reach-usd-29-97-billion-by-2034-driven-by-precision-oncology-and-high-plex-imaging 2026-07-09T23:09:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spatial-proteomics-market-poised-to-reach-usd-29-97-billion-by-2034-driven-by-precision-oncology-and-high-plex-imaging 2026-07-09T23:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-reshapes-scientific-leadership-pirman-promoted-to-head-of-discovery-car-transitions-to-chief-innovation-officer 2026-07-09T23:08:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-reshapes-scientific-leadership-pirman-promoted-to-head-of-discovery-car-transitions-to-chief-innovation-officer 2026-07-09T23:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/microneedle-technology-poised-to-transform-transdermal-drug-delivery-as-clinical-evidence-mounts 2026-07-09T23:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microneedle-technology-poised-to-transform-transdermal-drug-delivery-as-clinical-evidence-mounts 2026-07-09T23:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/six-gene-signature-in-hidden-liver-micrometastases-may-predict-colorectal-cancer-recurrence-risk 2026-07-09T22:10:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/six-gene-signature-in-hidden-liver-micrometastases-may-predict-colorectal-cancer-recurrence-risk 2026-07-09T22:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/space-station-bioprinting-breakthrough-human-liver-and-kidney-tissues-manufactured-in-orbit-for-the-first-time 2026-07-09T22:09:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/space-station-bioprinting-breakthrough-human-liver-and-kidney-tissues-manufactured-in-orbit-for-the-first-time 2026-07-09T22:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/nanoparticles-navigating-the-blood-brain-barrier-a-new-frontier-in-neurodegenerative-disease-therapy 2026-07-09T22:09:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoparticles-navigating-the-blood-brain-barrier-a-new-frontier-in-neurodegenerative-disease-therapy 2026-07-09T22:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/20-20-biolabs-charts-path-toward-medicare-reimbursement-for-onetesttm-mced-blood-test-reports-strong-q2-revenue-growth 2026-07-09T22:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/20-20-biolabs-charts-path-toward-medicare-reimbursement-for-onetesttm-mced-blood-test-reports-strong-q2-revenue-growth 2026-07-09T22:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/postoperative-pain-pipeline-2026-over-40-companies-advance-novel-therapies-with-extended-release-and-non-opioid-candidates 2026-07-09T21:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/postoperative-pain-pipeline-2026-over-40-companies-advance-novel-therapies-with-extended-release-and-non-opioid-candidates 2026-07-09T21:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/delcath-systems-doses-first-patient-in-phase-2-deluma-trial-of-hepzato-for-liver-dominant-metastatic-breast-cancer 2026-07-09T20:13:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delcath-systems-doses-first-patient-in-phase-2-deluma-trial-of-hepzato-for-liver-dominant-metastatic-breast-cancer 2026-07-09T20:13:05+00:00 hourly 0.9 https://trial.medpath.com/news/ucsf-and-samsung-launch-ambitious-1000-subject-remote-trial-to-map-brain-aging-through-wearable-technology 2026-07-09T20:13:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucsf-and-samsung-launch-ambitious-1000-subject-remote-trial-to-map-brain-aging-through-wearable-technology 2026-07-09T20:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/menopause-s-silent-symptoms-online-forums-reveal-cognitive-and-emotional-burden-missing-from-clinical-records 2026-07-09T20:11:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/menopause-s-silent-symptoms-online-forums-reveal-cognitive-and-emotional-burden-missing-from-clinical-records 2026-07-09T20:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/forte-biosciences-fb102-demonstrates-statistically-significant-efficacy-in-phase-1b-vitiligo-trial 2026-07-09T20:10:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forte-biosciences-fb102-demonstrates-statistically-significant-efficacy-in-phase-1b-vitiligo-trial 2026-07-09T20:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-and-mayo-clinic-launch-mi-bet-study-to-personalize-radioligand-therapy-in-advanced-prostate-cancer 2026-07-09T19:09:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ge-healthcare-and-mayo-clinic-launch-mi-bet-study-to-personalize-radioligand-therapy-in-advanced-prostate-cancer 2026-07-09T19:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-agonists-show-promise-in-reducing-pulmonary-fibrosis-from-long-covid-in-diabetic-patients-mouse-study-finds 2026-07-09T19:09:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-agonists-show-promise-in-reducing-pulmonary-fibrosis-from-long-covid-in-diabetic-patients-mouse-study-finds 2026-07-09T19:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/teleoperated-humanoid-robots-complete-first-ever-live-surgeries-in-preclinical-trial 2026-07-09T18:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teleoperated-humanoid-robots-complete-first-ever-live-surgeries-in-preclinical-trial 2026-07-09T18:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/rectal-spacers-show-acceptable-safety-in-locally-advanced-prostate-cancer-radiotherapy 2026-07-09T18:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rectal-spacers-show-acceptable-safety-in-locally-advanced-prostate-cancer-radiotherapy 2026-07-09T18:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/macrophage-metabolic-reprogramming-emerges-as-a-key-driver-of-chronic-transplant-rejection-and-a-new-therapeutic-target 2026-07-09T18:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/macrophage-metabolic-reprogramming-emerges-as-a-key-driver-of-chronic-transplant-rejection-and-a-new-therapeutic-target 2026-07-09T18:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/rybodyn-awarded-1-3m-dow-grant-to-advance-novel-antibody-therapies-against-cryptic-lung-cancer-targets 2026-07-09T18:10:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rybodyn-awarded-1-3m-dow-grant-to-advance-novel-antibody-therapies-against-cryptic-lung-cancer-targets 2026-07-09T18:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/ireland-launches-health-referral-scheme-for-first-time-personal-drug-possession-offenders 2026-07-09T18:10:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ireland-launches-health-referral-scheme-for-first-time-personal-drug-possession-offenders 2026-07-09T18:10:06+00:00 hourly 0.9 https://trial.medpath.com/news/southeast-asia-oncology-drug-access-market-to-reach-4-41-billion-by-2031-driven-by-biosimilar-adoption-and-precision-oncology 2026-07-09T17:08:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/southeast-asia-oncology-drug-access-market-to-reach-4-41-billion-by-2031-driven-by-biosimilar-adoption-and-precision-oncology 2026-07-09T17:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/b-cell-depletion-therapy-market-projected-to-reach-usd-62-6-billion-by-2036-driven-by-autoimmune-disease-demand 2026-07-09T17:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/b-cell-depletion-therapy-market-projected-to-reach-usd-62-6-billion-by-2036-driven-by-autoimmune-disease-demand 2026-07-09T17:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/dndi-and-serum-institute-of-india-partner-to-launch-global-phase-iii-trial-for-dengue-monoclonal-antibody 2026-07-09T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dndi-and-serum-institute-of-india-partner-to-launch-global-phase-iii-trial-for-dengue-monoclonal-antibody 2026-07-09T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/cystic-fibrosis-market-poised-for-transformation-as-cftr-modulators-gene-therapy-and-precision-medicine-drive-growth-through-2035 2026-07-09T17:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cystic-fibrosis-market-poised-for-transformation-as-cftr-modulators-gene-therapy-and-precision-medicine-drive-growth-through-2035 2026-07-09T17:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-annealing-boosts-drug-like-molecule-generation-beyond-training-data-d-wave-and-shionogi-study-shows 2026-07-09T17:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantum-annealing-boosts-drug-like-molecule-generation-beyond-training-data-d-wave-and-shionogi-study-shows 2026-07-09T17:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/aging-cells-shift-preference-toward-short-genes-revealing-new-anti-aging-therapeutic-targets 2026-07-09T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aging-cells-shift-preference-toward-short-genes-revealing-new-anti-aging-therapeutic-targets 2026-07-09T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/greenland-shark-s-dna-repair-mechanism-may-hold-key-to-preserving-human-vision 2026-07-09T16:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greenland-shark-s-dna-repair-mechanism-may-hold-key-to-preserving-human-vision 2026-07-09T16:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/arpa-h-launches-160-million-thrive-program-to-advance-custom-gene-editing-for-rare-diseases 2026-07-09T16:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arpa-h-launches-160-million-thrive-program-to-advance-custom-gene-editing-for-rare-diseases 2026-07-09T16:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/prime-medicine-advances-toward-clinical-milestones-following-patent-dispute-resolution 2026-07-09T16:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prime-medicine-advances-toward-clinical-milestones-following-patent-dispute-resolution 2026-07-09T16:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/arpa-h-thrive-awards-73-4-million-to-advance-personalized-gene-editing-platforms-for-rare-pediatric-diseases 2026-07-09T16:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arpa-h-thrive-awards-73-4-million-to-advance-personalized-gene-editing-platforms-for-rare-pediatric-diseases 2026-07-09T16:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-818-decree-draws-100-submissions-as-greater-bay-area-builds-integrated-clinical-research-ecosystem 2026-07-09T15:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-818-decree-draws-100-submissions-as-greater-bay-area-builds-integrated-clinical-research-ecosystem 2026-07-09T15:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/roche-discontinues-two-huntington-s-disease-programs-after-tominersen-fails-phase-ii-and-rg6496-hits-preclinical-safety-hurdle 2026-07-09T14:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-discontinues-two-huntington-s-disease-programs-after-tominersen-fails-phase-ii-and-rg6496-hits-preclinical-safety-hurdle 2026-07-09T14:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/godavari-biorefineries-secures-european-patent-for-novel-anti-cancer-drug-composition-with-enhanced-bioavailability 2026-07-09T14:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/godavari-biorefineries-secures-european-patent-for-novel-anti-cancer-drug-composition-with-enhanced-bioavailability 2026-07-09T14:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/adlai-nortye-advances-first-in-class-pan-ras-on-adc-an4035-into-phase-i-trial-for-ras-addicted-solid-tumors 2026-07-09T14:06:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adlai-nortye-advances-first-in-class-pan-ras-on-adc-an4035-into-phase-i-trial-for-ras-addicted-solid-tumors 2026-07-09T14:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/blue-earth-therapeutics-doses-first-patient-in-phase-1-trial-of-alpha-emitting-psma-radiopharmaceutical-for-mcrpc 2026-07-09T14:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blue-earth-therapeutics-doses-first-patient-in-phase-1-trial-of-alpha-emitting-psma-radiopharmaceutical-for-mcrpc 2026-07-09T14:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/small-molecule-api-market-to-reach-370-36-billion-by-2035-driven-by-oncology-demand-and-manufacturing-innovation 2026-07-09T13:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/small-molecule-api-market-to-reach-370-36-billion-by-2035-driven-by-oncology-demand-and-manufacturing-innovation 2026-07-09T13:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-q2-earnings-beat-drives-institutional-accumulation-as-pipeline-readouts-loom 2026-07-09T13:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-q2-earnings-beat-drives-institutional-accumulation-as-pipeline-readouts-loom 2026-07-09T13:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/bispecific-antibodies-face-a-manufacturing-bottleneck-as-drug-pipelines-surge 2026-07-09T13:06:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bispecific-antibodies-face-a-manufacturing-bottleneck-as-drug-pipelines-surge 2026-07-09T13:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/retinal-reserve-framework-functional-testing-and-systemic-biomarkers-enable-personalized-proactive-retinal-care 2026-07-09T13:06:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/retinal-reserve-framework-functional-testing-and-systemic-biomarkers-enable-personalized-proactive-retinal-care 2026-07-09T13:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/il-1-immune-pathway-identified-as-critical-defense-against-fatal-candida-albicans-infections 2026-07-09T12:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/il-1-immune-pathway-identified-as-critical-defense-against-fatal-candida-albicans-infections 2026-07-09T12:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/axxam-and-heartbeat-bio-forge-strategic-partnership-to-advance-human-relevant-cardiovascular-drug-discovery 2026-07-09T12:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axxam-and-heartbeat-bio-forge-strategic-partnership-to-advance-human-relevant-cardiovascular-drug-discovery 2026-07-09T12:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/easo-efad-and-ecpo-issue-landmark-consensus-nutritional-and-psychological-support-essential-for-glp-1-obesity-treatment-success 2026-07-09T09:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/easo-efad-and-ecpo-issue-landmark-consensus-nutritional-and-psychological-support-essential-for-glp-1-obesity-treatment-success 2026-07-09T09:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-wainua-falls-short-in-phase-iii-attr-cm-study-despite-positive-subgroup-signal 2026-07-09T09:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-wainua-falls-short-in-phase-iii-attr-cm-study-despite-positive-subgroup-signal 2026-07-09T09:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/dysport-becomes-first-botulinum-toxin-to-achieve-positive-phase-iii-results-in-both-episodic-and-chronic-migraine 2026-07-09T07:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dysport-becomes-first-botulinum-toxin-to-achieve-positive-phase-iii-results-in-both-episodic-and-chronic-migraine 2026-07-09T07:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/nationwide-survey-finds-only-one-third-of-spanish-microbiology-labs-perform-quantitative-hbsag-testing 2026-07-09T06:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nationwide-survey-finds-only-one-third-of-spanish-microbiology-labs-perform-quantitative-hbsag-testing 2026-07-09T06:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/environmental-bacteria-act-as-stealth-reservoirs-for-instant-extreme-antibiotic-resistance-in-lung-infections 2026-07-09T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/environmental-bacteria-act-as-stealth-reservoirs-for-instant-extreme-antibiotic-resistance-in-lung-infections 2026-07-09T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-german-expert-consensus-provides-first-risk-based-recommendations-for-snpwt-use-in-closed-surgical-incisions 2026-07-09T06:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-german-expert-consensus-provides-first-risk-based-recommendations-for-snpwt-use-in-closed-surgical-incisions 2026-07-09T06:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/rfk-jr-s-hhs-moves-to-create-covid-19-vaccine-injury-table-raising-scientific-scrutiny-concerns 2026-07-09T04:14:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rfk-jr-s-hhs-moves-to-create-covid-19-vaccine-injury-table-raising-scientific-scrutiny-concerns 2026-07-09T04:14:19+00:00 hourly 0.9 https://trial.medpath.com/news/ascendis-pharma-reports-positive-transcon-cnp-clinical-data-amid-revenue-growth-to-720-million 2026-07-09T02:56:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascendis-pharma-reports-positive-transcon-cnp-clinical-data-amid-revenue-growth-to-720-million 2026-07-09T02:56:33+00:00 hourly 0.9 https://trial.medpath.com/news/antihistamines-and-colchicine-show-modest-short-term-benefit-for-long-covid-fatigue-in-landmark-uk-trial 2026-07-09T00:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antihistamines-and-colchicine-show-modest-short-term-benefit-for-long-covid-fatigue-in-landmark-uk-trial 2026-07-09T00:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/sarcopenia-emerges-as-a-modifiable-prognostic-factor-in-breast-cancer-driving-calls-for-standardized-screening-and-multimodal-intervention 2026-07-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarcopenia-emerges-as-a-modifiable-prognostic-factor-in-breast-cancer-driving-calls-for-standardized-screening-and-multimodal-intervention 2026-07-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/multistate-salmonella-outbreak-linked-to-cage-free-eggs-escalated-to-fda-class-i-recall 2026-07-08T23:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multistate-salmonella-outbreak-linked-to-cage-free-eggs-escalated-to-fda-class-i-recall 2026-07-08T23:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/parental-stress-drives-increased-screen-time-in-young-children-study-finds 2026-07-08T23:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parental-stress-drives-increased-screen-time-in-young-children-study-finds 2026-07-08T23:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/ohsu-board-votes-to-transition-primate-research-center-toward-nonanimal-human-based-methods 2026-07-08T23:07:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ohsu-board-votes-to-transition-primate-research-center-toward-nonanimal-human-based-methods 2026-07-08T23:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/abeona-therapeutics-advances-commercial-rollout-of-zevaskyn-cell-therapy-amid-strong-analyst-support 2026-07-08T21:09:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abeona-therapeutics-advances-commercial-rollout-of-zevaskyn-cell-therapy-amid-strong-analyst-support 2026-07-08T21:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-moves-to-eliminate-adequate-provision-rule-threatening-broadcast-pharma-advertising 2026-07-08T21:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-moves-to-eliminate-adequate-provision-rule-threatening-broadcast-pharma-advertising 2026-07-08T21:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-pharma-s-1-billion-equity-raise-fuels-pipeline-momentum-amid-regulatory-progress 2026-07-08T20:13:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-pharma-s-1-billion-equity-raise-fuels-pipeline-momentum-amid-regulatory-progress 2026-07-08T20:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/gleneagles-hospital-chennai-achieves-complete-remission-in-rare-brain-lymphoma-using-india-s-indigenous-car-t-therapy-nexcar19 2026-07-08T20:13:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gleneagles-hospital-chennai-achieves-complete-remission-in-rare-brain-lymphoma-using-india-s-indigenous-car-t-therapy-nexcar19 2026-07-08T20:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/diet-microbiome-synergy-drives-immunotherapy-efficacy-in-obesity-landmark-nature-study-reveals 2026-07-08T20:13:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diet-microbiome-synergy-drives-immunotherapy-efficacy-in-obesity-landmark-nature-study-reveals 2026-07-08T20:13:30+00:00 hourly 0.9 https://trial.medpath.com/news/consumer-reports-investigation-finds-concerning-arsenic-levels-across-all-52-rice-products-tested 2026-07-08T20:13:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/consumer-reports-investigation-finds-concerning-arsenic-levels-across-all-52-rice-products-tested 2026-07-08T20:13:19+00:00 hourly 0.9 https://trial.medpath.com/news/altruist-biologics-hangzhou-adc-facility-receives-first-trilateral-provincial-regulatory-approval-for-segmented-manufacturing 2026-07-08T20:11:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altruist-biologics-hangzhou-adc-facility-receives-first-trilateral-provincial-regulatory-approval-for-segmented-manufacturing 2026-07-08T20:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/lsu-and-fmol-health-award-1-6m-to-seven-research-teams-targeting-louisiana-s-critical-health-challenges 2026-07-08T20:11:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lsu-and-fmol-health-award-1-6m-to-seven-research-teams-targeting-louisiana-s-critical-health-challenges 2026-07-08T20:11:39+00:00 hourly 0.9 https://trial.medpath.com/news/immune-surveillance-and-evasion-of-senescent-cells-new-therapeutic-frontiers-in-cancer-and-aging 2026-07-08T20:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immune-surveillance-and-evasion-of-senescent-cells-new-therapeutic-frontiers-in-cancer-and-aging 2026-07-08T20:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/hypoxia-therapy-dramatically-extends-lifespan-in-mouse-model-of-htra2-linked-mitochondrial-disease 2026-07-08T19:10:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hypoxia-therapy-dramatically-extends-lifespan-in-mouse-model-of-htra2-linked-mitochondrial-disease 2026-07-08T19:10:35+00:00 hourly 0.9 https://trial.medpath.com/news/nfl-players-face-fourfold-higher-neurodegenerative-mortality-in-largest-ever-cohort-study 2026-07-08T19:10:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nfl-players-face-fourfold-higher-neurodegenerative-mortality-in-largest-ever-cohort-study 2026-07-08T19:10:01+00:00 hourly 0.9 https://trial.medpath.com/news/aws-graphrag-deployment-cuts-drug-research-cycles-by-87-compressing-six-month-screening-to-three-weeks 2026-07-08T19:09:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aws-graphrag-deployment-cuts-drug-research-cycles-by-87-compressing-six-month-screening-to-three-weeks 2026-07-08T19:09:31+00:00 hourly 0.9 https://trial.medpath.com/news/dea-proposes-permanent-schedule-i-ban-for-tianeptine-the-original-gas-station-heroin 2026-07-08T19:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dea-proposes-permanent-schedule-i-ban-for-tianeptine-the-original-gas-station-heroin 2026-07-08T19:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-koala-reveals-81-hidden-genetic-drivers-of-triple-negative-breast-cancer-in-living-tumors 2026-07-08T18:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-koala-reveals-81-hidden-genetic-drivers-of-triple-negative-breast-cancer-in-living-tumors 2026-07-08T18:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/asco-issues-new-guidelines-for-systemic-thyroid-cancer-therapy-amid-rapid-molecular-advances 2026-07-08T18:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asco-issues-new-guidelines-for-systemic-thyroid-cancer-therapy-amid-rapid-molecular-advances 2026-07-08T18:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-elahere-shows-positive-phase-2-data-in-ovarian-cancer-strengthening-oncology-pipeline 2026-07-08T18:07:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-elahere-shows-positive-phase-2-data-in-ovarian-cancer-strengthening-oncology-pipeline 2026-07-08T18:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-classifies-lupin-s-prednisolone-acetate-eye-drops-recall-as-class-ii-over-foreign-particulate-contamination 2026-07-08T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-classifies-lupin-s-prednisolone-acetate-eye-drops-recall-as-class-ii-over-foreign-particulate-contamination 2026-07-08T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/enlife-research-raises-6-crore-seed-funding-to-develop-ai-powered-blood-test-for-early-alzheimer-s-detection 2026-07-08T16:12:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enlife-research-raises-6-crore-seed-funding-to-develop-ai-powered-blood-test-for-early-alzheimer-s-detection 2026-07-08T16:12:09+00:00 hourly 0.9 https://trial.medpath.com/news/dea-moves-to-temporarily-ban-synthetic-kratom-compound-7-oh-classifying-it-as-schedule-i 2026-07-08T16:11:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dea-moves-to-temporarily-ban-synthetic-kratom-compound-7-oh-classifying-it-as-schedule-i 2026-07-08T16:11:59+00:00 hourly 0.9 https://trial.medpath.com/news/allotera-therapeutics-closes-35-million-financing-bringing-total-to-150-million-for-pivotal-stage-off-the-shelf-car-t-therapy-in-t-cell-cancers 2026-07-08T16:11:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allotera-therapeutics-closes-35-million-financing-bringing-total-to-150-million-for-pivotal-stage-off-the-shelf-car-t-therapy-in-t-cell-cancers 2026-07-08T16:11:29+00:00 hourly 0.9 https://trial.medpath.com/news/lung-transplant-achieves-100-one-year-survival-in-select-patients-with-terminal-lung-limited-nsclc-landmark-dream-registry-study-shows 2026-07-08T16:09:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lung-transplant-achieves-100-one-year-survival-in-select-patients-with-terminal-lung-limited-nsclc-landmark-dream-registry-study-shows 2026-07-08T16:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-pharma-industry-charts-innovation-driven-future-at-landmark-beijing-conference 2026-07-08T16:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-pharma-industry-charts-innovation-driven-future-at-landmark-beijing-conference 2026-07-08T16:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/porton-advanced-s-uc-mscs-cell-bank-for-exosome-manufacturing-receives-u-s-fda-drug-master-file-acceptance 2026-07-08T15:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/porton-advanced-s-uc-mscs-cell-bank-for-exosome-manufacturing-receives-u-s-fda-drug-master-file-acceptance 2026-07-08T15:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/prime-medicine-wins-arbitration-against-beam-therapeutics-over-gene-editing-therapy-for-aatd 2026-07-08T15:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prime-medicine-wins-arbitration-against-beam-therapeutics-over-gene-editing-therapy-for-aatd 2026-07-08T15:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/former-merck-and-nasa-leaders-join-spacemd-to-accelerate-space-based-pharmaceutical-r-d 2026-07-08T15:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-merck-and-nasa-leaders-join-spacemd-to-accelerate-space-based-pharmaceutical-r-d 2026-07-08T15:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-bifidobacterium-shows-dual-promise-oral-vaccine-boosts-anti-tumor-immunity-in-phase-i-trial-as-nci-funds-systemic-delivery-platform-for-pancreatic-cancer 2026-07-08T15:06:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-bifidobacterium-shows-dual-promise-oral-vaccine-boosts-anti-tumor-immunity-in-phase-i-trial-as-nci-funds-systemic-delivery-platform-for-pancreatic-cancer 2026-07-08T15:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/spectrum-science-appoints-industry-veteran-marie-emms-as-president-of-clinical-business 2026-07-08T15:06:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spectrum-science-appoints-industry-veteran-marie-emms-as-president-of-clinical-business 2026-07-08T15:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/vaccinex-to-present-new-biomarker-data-supporting-expanded-phase-2b-trial-of-pepinemab-in-early-alzheimer-s-disease 2026-07-08T15:06:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaccinex-to-present-new-biomarker-data-supporting-expanded-phase-2b-trial-of-pepinemab-in-early-alzheimer-s-disease 2026-07-08T15:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-s-dark-proteome-emerges-as-a-new-frontier-for-drug-targets-and-immunotherapy 2026-07-08T15:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-s-dark-proteome-emerges-as-a-new-frontier-for-drug-targets-and-immunotherapy 2026-07-08T15:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/tardive-dyskinesia-market-projected-to-reach-usd-4-4-billion-by-2036-growing-at-8-1-cagr-amid-pipeline-innovation 2026-07-08T14:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tardive-dyskinesia-market-projected-to-reach-usd-4-4-billion-by-2036-growing-at-8-1-cagr-amid-pipeline-innovation 2026-07-08T14:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-reshuffles-board-with-ex-biogen-cfo-michael-mcdonnell-amid-950m-patent-settlement-and-eu-rsv-supply-deal 2026-07-08T14:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-reshuffles-board-with-ex-biogen-cfo-michael-mcdonnell-amid-950m-patent-settlement-and-eu-rsv-supply-deal 2026-07-08T14:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/new-international-guideline-published-for-diagnosing-and-treating-allan-herndon-dudley-syndrome 2026-07-08T14:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-international-guideline-published-for-diagnosing-and-treating-allan-herndon-dudley-syndrome 2026-07-08T14:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/oman-moves-closer-to-adopting-national-biotechnology-strategy 2026-07-08T14:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oman-moves-closer-to-adopting-national-biotechnology-strategy 2026-07-08T14:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/niagen-bioscience-launches-nb4168-a-proprietary-nad-precursor-as-first-pharmaceutical-candidate-for-ataxia-telangiectasia 2026-07-08T14:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/niagen-bioscience-launches-nb4168-a-proprietary-nad-precursor-as-first-pharmaceutical-candidate-for-ataxia-telangiectasia 2026-07-08T14:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/nautilus-biotechnology-to-report-second-quarter-2026-financial-results-on-july-28 2026-07-08T14:06:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nautilus-biotechnology-to-report-second-quarter-2026-financial-results-on-july-28 2026-07-08T14:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/global-hotspots-where-breast-cancer-and-atrial-fibrillation-overlap-reveal-smoking-and-alcohol-as-shared-modifiable-risk-factors 2026-07-08T13:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-hotspots-where-breast-cancer-and-atrial-fibrillation-overlap-reveal-smoking-and-alcohol-as-shared-modifiable-risk-factors 2026-07-08T13:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/nsf-launches-project-triad-to-integrate-quantum-sensing-networking-and-computing-for-real-world-applications-including-precision-medicine 2026-07-08T13:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nsf-launches-project-triad-to-integrate-quantum-sensing-networking-and-computing-for-real-world-applications-including-precision-medicine 2026-07-08T13:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/xiaflex-meets-phase-iii-primary-endpoint-in-plantar-fibromatosis-setting-stage-for-first-ever-fda-approval 2026-07-08T13:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xiaflex-meets-phase-iii-primary-endpoint-in-plantar-fibromatosis-setting-stage-for-first-ever-fda-approval 2026-07-08T13:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rmat-designation-to-emmecell-s-eo2002-cell-therapy-for-corneal-edema 2026-07-08T13:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-rmat-designation-to-emmecell-s-eo2002-cell-therapy-for-corneal-edema 2026-07-08T13:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/chemomab-and-scipher-medicine-merge-to-advance-nebokitug-in-ai-powered-phase-2-rheumatoid-arthritis-trial 2026-07-08T13:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chemomab-and-scipher-medicine-merge-to-advance-nebokitug-in-ai-powered-phase-2-rheumatoid-arthritis-trial 2026-07-08T13:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/the-ai-trust-gap-in-pharma-r-d-why-scientists-are-hesitating-and-what-must-change 2026-07-08T13:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-ai-trust-gap-in-pharma-r-d-why-scientists-are-hesitating-and-what-must-change 2026-07-08T13:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/u-of-t-and-mcmaster-anchor-40-million-genesys-university-seed-fund-to-retain-canadian-life-sciences-innovation 2026-07-08T13:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-of-t-and-mcmaster-anchor-40-million-genesys-university-seed-fund-to-retain-canadian-life-sciences-innovation 2026-07-08T13:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/restart-life-sciences-reports-146-sequential-revenue-growth-and-details-next-generation-product-pipeline 2026-07-08T13:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/restart-life-sciences-reports-146-sequential-revenue-growth-and-details-next-generation-product-pipeline 2026-07-08T13:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/sheffield-students-produce-life-changing-rare-disease-guides-for-families-worldwide 2026-07-08T13:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sheffield-students-produce-life-changing-rare-disease-guides-for-families-worldwide 2026-07-08T13:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/mindrank-secures-52m-series-b-to-advance-ai-native-drug-r-d-engine-and-oral-glp-1-agonist-mdr-001-into-phase-iii 2026-07-08T13:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindrank-secures-52m-series-b-to-advance-ai-native-drug-r-d-engine-and-oral-glp-1-agonist-mdr-001-into-phase-iii 2026-07-08T13:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/okyo-pharma-accelerates-urcosimod-into-global-phase-3-pivotal-trial-for-neuropathic-corneal-pain-following-fda-alignment 2026-07-08T12:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/okyo-pharma-accelerates-urcosimod-into-global-phase-3-pivotal-trial-for-neuropathic-corneal-pain-following-fda-alignment 2026-07-08T12:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/defence-therapeutics-appoints-dr-ryan-simms-as-coo-and-head-of-radiopharmaceutical-programs 2026-07-08T11:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/defence-therapeutics-appoints-dr-ryan-simms-as-coo-and-head-of-radiopharmaceutical-programs 2026-07-08T11:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/non-invasive-brush-biopsy-test-detects-oral-squamous-cell-carcinoma-with-95-5-accuracy-in-under-one-hour 2026-07-08T11:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/non-invasive-brush-biopsy-test-detects-oral-squamous-cell-carcinoma-with-95-5-accuracy-in-under-one-hour 2026-07-08T11:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/asia-s-longevity-economy-boom-luxury-clinics-surge-amid-scientific-scrutiny-and-policy-gaps 2026-07-08T10:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asia-s-longevity-economy-boom-luxury-clinics-surge-amid-scientific-scrutiny-and-policy-gaps 2026-07-08T10:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/governed-hybrid-model-emerges-as-the-next-competitive-frontier-in-clinical-research-site-strategy 2026-07-08T10:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/governed-hybrid-model-emerges-as-the-next-competitive-frontier-in-clinical-research-site-strategy 2026-07-08T10:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/ai-can-calculate-medical-probabilities-but-it-cannot-answer-the-question-that-matters-most 2026-07-08T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-can-calculate-medical-probabilities-but-it-cannot-answer-the-question-that-matters-most 2026-07-08T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/genespire-and-sr-tiget-demonstrate-durable-preclinical-efficacy-of-liver-directed-gene-therapy-for-methylmalonic-acidemia 2026-07-08T09:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genespire-and-sr-tiget-demonstrate-durable-preclinical-efficacy-of-liver-directed-gene-therapy-for-methylmalonic-acidemia 2026-07-08T09:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/ai-orchestration-not-more-outreach-is-key-to-fixing-healthcare-s-patient-access-problem 2026-07-08T07:09:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-orchestration-not-more-outreach-is-key-to-fixing-healthcare-s-patient-access-problem 2026-07-08T07:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/bio-rad-launches-vericheck-ddpcr-kit-portfolio-for-cell-and-gene-therapy-quality-control-on-qx700-platform 2026-07-08T07:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-rad-launches-vericheck-ddpcr-kit-portfolio-for-cell-and-gene-therapy-quality-control-on-qx700-platform 2026-07-08T07:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/catholic-health-and-hiccc-at-nyp-columbia-partner-to-expand-cancer-clinical-trial-access-across-long-island 2026-07-08T07:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catholic-health-and-hiccc-at-nyp-columbia-partner-to-expand-cancer-clinical-trial-access-across-long-island 2026-07-08T07:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/kuehnle-agrosystems-closes-series-b-financing-to-commercialise-world-first-dark-fermentation-natural-astaxanthin 2026-07-08T07:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kuehnle-agrosystems-closes-series-b-financing-to-commercialise-world-first-dark-fermentation-natural-astaxanthin 2026-07-08T07:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/coregen-receives-fda-clearance-for-first-in-human-trial-of-crg-150-a-novel-adoptive-cell-therapy-targeting-src-3-in-multiple-solid-tumors 2026-07-08T06:09:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coregen-receives-fda-clearance-for-first-in-human-trial-of-crg-150-a-novel-adoptive-cell-therapy-targeting-src-3-in-multiple-solid-tumors 2026-07-08T06:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/bma-warns-ps16-7-million-cut-to-medical-academic-funding-threatens-uk-research-innovation-and-nhs-resilience 2026-07-08T06:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bma-warns-ps16-7-million-cut-to-medical-academic-funding-threatens-uk-research-innovation-and-nhs-resilience 2026-07-08T06:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/australian-tga-issues-updated-safety-warning-on-ashwagandha-and-very-rare-risk-of-liver-injury 2026-07-08T03:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-tga-issues-updated-safety-warning-on-ashwagandha-and-very-rare-risk-of-liver-injury 2026-07-08T03:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/brain-cell-changes-reveal-why-parkinson-s-disease-affects-more-men-than-women 2026-07-08T02:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-cell-changes-reveal-why-parkinson-s-disease-affects-more-men-than-women 2026-07-08T02:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/gvhd-pipeline-2026-cell-based-microbiome-and-targeted-therapies-reshape-treatment-landscape 2026-07-08T01:07:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gvhd-pipeline-2026-cell-based-microbiome-and-targeted-therapies-reshape-treatment-landscape 2026-07-08T01:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-enters-agreement-with-vivani-medical-to-evaluate-ultra-long-acting-semaglutide-implant-for-chronic-weight-management 2026-07-08T01:07:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-enters-agreement-with-vivani-medical-to-evaluate-ultra-long-acting-semaglutide-implant-for-chronic-weight-management 2026-07-08T01:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/ai-reveals-previously-invisible-cortical-lesions-on-conventional-mri-scans-transforming-ms-research-and-clinical-care 2026-07-08T00:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-reveals-previously-invisible-cortical-lesions-on-conventional-mri-scans-transforming-ms-research-and-clinical-care 2026-07-08T00:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/spear-bio-to-unveil-first-commercially-available-singleplex-emtbr-tau-immunoassay-and-novel-ptau-217-assay-at-aaic-2026 2026-07-08T00:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spear-bio-to-unveil-first-commercially-available-singleplex-emtbr-tau-immunoassay-and-novel-ptau-217-assay-at-aaic-2026 2026-07-08T00:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/ubc-faculty-of-medicine-researchers-awarded-over-5-8m-in-nserc-discovery-grants-for-biomedical-innovation 2026-07-08T00:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ubc-faculty-of-medicine-researchers-awarded-over-5-8m-in-nserc-discovery-grants-for-biomedical-innovation 2026-07-08T00:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/plasma-nfl-and-gfap-fail-as-biomarkers-in-myasthenia-gravis-controlled-study-finds 2026-07-08T00:07:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plasma-nfl-and-gfap-fail-as-biomarkers-in-myasthenia-gravis-controlled-study-finds 2026-07-08T00:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/novel-antibody-drug-conjugate-eliminates-residual-cancer-cells-in-majority-of-patients-with-b-cell-all 2026-07-08T00:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-antibody-drug-conjugate-eliminates-residual-cancer-cells-in-majority-of-patients-with-b-cell-all 2026-07-08T00:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/healome-therapeutics-raises-ps2-million-seed-funding-to-advance-eye-drop-matrix-platform-for-ocular-surface-diseases 2026-07-07T22:10:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healome-therapeutics-raises-ps2-million-seed-funding-to-advance-eye-drop-matrix-platform-for-ocular-surface-diseases 2026-07-07T22:10:35+00:00 hourly 0.9 https://trial.medpath.com/news/clinuvel-announces-strategic-restructure-and-us-relocation-to-unlock-pipeline-value-led-by-vitiligo-program 2026-07-07T22:10:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinuvel-announces-strategic-restructure-and-us-relocation-to-unlock-pipeline-value-led-by-vitiligo-program 2026-07-07T22:10:20+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-secures-fda-rare-pediatric-disease-designation-for-antisense-oligonucleotide-therapy-vca-894a-in-cmt2s 2026-07-07T22:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanda-pharmaceuticals-secures-fda-rare-pediatric-disease-designation-for-antisense-oligonucleotide-therapy-vca-894a-in-cmt2s 2026-07-07T22:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/altasciences-and-evidence-matters-achieve-ai-breakthrough-in-nonclinical-drug-development-automation 2026-07-07T22:10:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altasciences-and-evidence-matters-achieve-ai-breakthrough-in-nonclinical-drug-development-automation 2026-07-07T22:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-advances-dry-mrna-vaccine-patch-design-offering-path-beyond-cold-chain-storage 2026-07-07T22:10:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-study-advances-dry-mrna-vaccine-patch-design-offering-path-beyond-cold-chain-storage 2026-07-07T22:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/men-face-significantly-higher-risk-of-late-stage-cancer-diagnosis-across-20-solid-tumor-types-nci-study-finds 2026-07-07T22:10:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/men-face-significantly-higher-risk-of-late-stage-cancer-diagnosis-across-20-solid-tumor-types-nci-study-finds 2026-07-07T22:10:12+00:00 hourly 0.9 https://trial.medpath.com/news/the-ethics-of-being-left-out-of-health-research-when-over-protection-becomes-exclusion 2026-07-07T22:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-ethics-of-being-left-out-of-health-research-when-over-protection-becomes-exclusion 2026-07-07T22:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/manganese-ferrite-nanoparticles-generate-57-more-heating-power-than-cobalt-ferrite-in-magnetic-hyperthermia-cancer-research 2026-07-07T20:09:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/manganese-ferrite-nanoparticles-generate-57-more-heating-power-than-cobalt-ferrite-in-magnetic-hyperthermia-cancer-research 2026-07-07T20:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/legionnaires-disease-outbreak-in-manhattan-s-upper-east-side-23-cases-confirmed-health-officials-urge-early-detection 2026-07-07T20:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/legionnaires-disease-outbreak-in-manhattan-s-upper-east-side-23-cases-confirmed-health-officials-urge-early-detection 2026-07-07T20:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/discount-or-validation-the-shifting-economics-of-western-pharma-s-licensing-of-chinese-assets 2026-07-07T20:09:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/discount-or-validation-the-shifting-economics-of-western-pharma-s-licensing-of-chinese-assets 2026-07-07T20:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/southern-nevada-s-bioscience-ecosystem-gains-global-attention-at-bio-international-convention-2026 2026-07-07T20:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/southern-nevada-s-bioscience-ecosystem-gains-global-attention-at-bio-international-convention-2026 2026-07-07T20:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/missing-rna-tests-skew-hepatitis-c-cure-rates-nationwide-u-s-cohort-study-finds 2026-07-07T19:11:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/missing-rna-tests-skew-hepatitis-c-cure-rates-nationwide-u-s-cohort-study-finds 2026-07-07T19:11:27+00:00 hourly 0.9 https://trial.medpath.com/news/life-sciences-tools-services-q1-2026-earnings-illumina-bruker-lead-as-10x-genomics-revenue-declines 2026-07-07T19:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/life-sciences-tools-services-q1-2026-earnings-illumina-bruker-lead-as-10x-genomics-revenue-declines 2026-07-07T19:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-wyoming-inbre-program-receives-18-9m-nih-grant-to-bolster-biomedical-research-and-education 2026-07-07T19:10:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-wyoming-inbre-program-receives-18-9m-nih-grant-to-bolster-biomedical-research-and-education 2026-07-07T19:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/galidesivir-cleared-for-compassionate-use-against-bundibugyo-ebola-in-uganda 2026-07-07T18:09:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galidesivir-cleared-for-compassionate-use-against-bundibugyo-ebola-in-uganda 2026-07-07T18:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/mount-sinai-launches-7-2m-nih-funded-center-to-advance-personalized-peanut-allergy-treatments 2026-07-07T18:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mount-sinai-launches-7-2m-nih-funded-center-to-advance-personalized-peanut-allergy-treatments 2026-07-07T18:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/phthalate-exposure-during-pregnancy-linked-to-shorter-gestation-and-lower-birth-weight-in-large-us-cohort 2026-07-07T17:12:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phthalate-exposure-during-pregnancy-linked-to-shorter-gestation-and-lower-birth-weight-in-large-us-cohort 2026-07-07T17:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/pmv-pharmaceuticals-advances-p53-targeted-precision-oncology-pipeline 2026-07-07T17:12:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pmv-pharmaceuticals-advances-p53-targeted-precision-oncology-pipeline 2026-07-07T17:12:08+00:00 hourly 0.9 https://trial.medpath.com/news/mild-sleep-deprivation-leads-to-measurable-weight-gain-columbia-study-finds 2026-07-07T17:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mild-sleep-deprivation-leads-to-measurable-weight-gain-columbia-study-finds 2026-07-07T17:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/inaugural-aacr-d3-conference-convenes-leaders-across-oncology-drug-development-to-catalyze-innovation 2026-07-07T17:12:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inaugural-aacr-d3-conference-convenes-leaders-across-oncology-drug-development-to-catalyze-innovation 2026-07-07T17:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/protagonist-therapeutics-rallies-on-rusfertide-nda-acceptance-and-icotyde-fda-approval 2026-07-07T17:11:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protagonist-therapeutics-rallies-on-rusfertide-nda-acceptance-and-icotyde-fda-approval 2026-07-07T17:11:59+00:00 hourly 0.9 https://trial.medpath.com/news/ccran-and-signal49-research-launch-phase-ii-initiative-to-make-comprehensive-genomic-profiling-a-standard-of-care-for-metastatic-cancer-in-canada 2026-07-07T17:09:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ccran-and-signal49-research-launch-phase-ii-initiative-to-make-comprehensive-genomic-profiling-a-standard-of-care-for-metastatic-cancer-in-canada 2026-07-07T17:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/samhsa-unveils-281-million-in-moud-grants-while-restricting-harm-reduction-and-mandating-psychosocial-services 2026-07-07T17:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samhsa-unveils-281-million-in-moud-grants-while-restricting-harm-reduction-and-mandating-psychosocial-services 2026-07-07T17:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/serum-reg3a-emerges-as-promising-blood-based-biomarker-for-ulcerative-colitis-disease-monitoring 2026-07-07T17:08:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serum-reg3a-emerges-as-promising-blood-based-biomarker-for-ulcerative-colitis-disease-monitoring 2026-07-07T17:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/splashbio-launches-as-independent-platform-company-to-tackle-alzheimer-s-trial-screen-failures-with-biomarker-driven-pre-screening 2026-07-07T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/splashbio-launches-as-independent-platform-company-to-tackle-alzheimer-s-trial-screen-failures-with-biomarker-driven-pre-screening 2026-07-07T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/radiotherapy-reprograms-immune-response-in-cutaneous-t-cell-lymphoma-revealing-new-biomarkers-for-recurrence 2026-07-07T16:09:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiotherapy-reprograms-immune-response-in-cutaneous-t-cell-lymphoma-revealing-new-biomarkers-for-recurrence 2026-07-07T16:09:17+00:00 hourly 0.9 https://trial.medpath.com/news/cu-anschutz-researchers-develop-nonhormonal-therapy-targeting-root-cause-of-genitourinary-syndrome-of-menopause 2026-07-07T16:09:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cu-anschutz-researchers-develop-nonhormonal-therapy-targeting-root-cause-of-genitourinary-syndrome-of-menopause 2026-07-07T16:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/eha-2026-lifetime-achievement-awardee-claire-harrison-reflects-on-jak-inhibitors-and-the-future-of-myeloproliferative-neoplasms 2026-07-07T16:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eha-2026-lifetime-achievement-awardee-claire-harrison-reflects-on-jak-inhibitors-and-the-future-of-myeloproliferative-neoplasms 2026-07-07T16:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/hetero-launches-once-weekly-semaglutide-truglyx-in-kenya-as-novo-nordisk-brings-ozempic-and-wegovy-to-market 2026-07-07T15:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hetero-launches-once-weekly-semaglutide-truglyx-in-kenya-as-novo-nordisk-brings-ozempic-and-wegovy-to-market 2026-07-07T15:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-announces-322-layoffs-at-east-hanover-facility-triggering-warn-act-investigation 2026-07-07T15:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-announces-322-layoffs-at-east-hanover-facility-triggering-warn-act-investigation 2026-07-07T15:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbiome-changes-can-signal-future-type-2-diabetes-risk-years-before-diagnosis-large-swedish-study-finds 2026-07-07T15:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-microbiome-changes-can-signal-future-type-2-diabetes-risk-years-before-diagnosis-large-swedish-study-finds 2026-07-07T15:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/cyllene-therapeutics-raises-eur33m-series-c-to-advance-hsv-1-gene-therapy-for-neurogenic-bladder-conditions 2026-07-07T15:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyllene-therapeutics-raises-eur33m-series-c-to-advance-hsv-1-gene-therapy-for-neurogenic-bladder-conditions 2026-07-07T15:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-forms-first-ever-academic-medical-center-clinical-trials-alliance-with-cu-anschutz-uchealth-and-children-s-hospital-colorado 2026-07-07T15:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-forms-first-ever-academic-medical-center-clinical-trials-alliance-with-cu-anschutz-uchealth-and-children-s-hospital-colorado 2026-07-07T15:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/saol-therapeutics-resubmits-nda-for-sl1009-dca-in-pyruvate-dehydrogenase-complex-deficiency-following-fda-alignment 2026-07-07T15:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saol-therapeutics-resubmits-nda-for-sl1009-dca-in-pyruvate-dehydrogenase-complex-deficiency-following-fda-alignment 2026-07-07T15:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/teva-to-advance-anti-il-15-antibody-tev-408-into-phase-2b-for-vitiligo-following-promising-phase-1b-results 2026-07-07T14:06:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-to-advance-anti-il-15-antibody-tev-408-into-phase-2b-for-vitiligo-following-promising-phase-1b-results 2026-07-07T14:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/point-of-care-molecular-testing-nearly-doubles-appropriate-treatment-for-vaginitis-randomized-trial-shows 2026-07-07T14:06:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/point-of-care-molecular-testing-nearly-doubles-appropriate-treatment-for-vaginitis-randomized-trial-shows 2026-07-07T14:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/the-craft-curation-model-independent-small-batch-cultivators-reshape-new-jersey-s-cannabis-market 2026-07-07T13:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-craft-curation-model-independent-small-batch-cultivators-reshape-new-jersey-s-cannabis-market 2026-07-07T13:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/vitalant-reports-critical-type-o-blood-shortage-at-two-year-low-urges-immediate-donations 2026-07-07T12:11:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vitalant-reports-critical-type-o-blood-shortage-at-two-year-low-urges-immediate-donations 2026-07-07T12:11:54+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-cde-launches-pioneer-program-formally-integrating-organoids-and-organ-on-a-chip-into-drug-regulatory-evaluation 2026-07-07T12:11:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-cde-launches-pioneer-program-formally-integrating-organoids-and-organ-on-a-chip-into-drug-regulatory-evaluation 2026-07-07T12:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/rio-trial-long-acting-bnabs-3bnc117-ls-and-10-1074-ls-delay-hiv-rebound-and-accelerate-reservoir-decay-after-treatment-interruption 2026-07-07T12:11:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rio-trial-long-acting-bnabs-3bnc117-ls-and-10-1074-ls-delay-hiv-rebound-and-accelerate-reservoir-decay-after-treatment-interruption 2026-07-07T12:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/tiximed-initiates-phase-1b-mad-study-of-oral-txnip-inhibitor-tix100-for-type-1-diabetes 2026-07-07T11:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tiximed-initiates-phase-1b-mad-study-of-oral-txnip-inhibitor-tix100-for-type-1-diabetes 2026-07-07T11:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/insurers-pocket-copay-assistance-funds-meant-to-defray-patient-drug-costs-leaving-patients-financially-devastated 2026-07-07T10:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insurers-pocket-copay-assistance-funds-meant-to-defray-patient-drug-costs-leaving-patients-financially-devastated 2026-07-07T10:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/measurable-residual-disease-as-surrogate-endpoint-in-cll-trials-methodological-concerns-raised-over-meta-analysis-findings 2026-07-07T10:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/measurable-residual-disease-as-surrogate-endpoint-in-cll-trials-methodological-concerns-raised-over-meta-analysis-findings 2026-07-07T10:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/exosome-drug-delivery-services-market-poised-to-reach-24-33-billion-by-2035-growing-at-17-5-cagr 2026-07-07T10:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exosome-drug-delivery-services-market-poised-to-reach-24-33-billion-by-2035-growing-at-17-5-cagr 2026-07-07T10:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/lsu-vet-med-launches-2026-summer-scholars-program-with-17-veterinary-students-pursuing-biomedical-research 2026-07-07T09:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lsu-vet-med-launches-2026-summer-scholars-program-with-17-veterinary-students-pursuing-biomedical-research 2026-07-07T09:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/roche-to-present-new-trontinemab-long-term-data-and-preventron-phase-iii-trial-design-at-aaic-2026 2026-07-07T09:08:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-to-present-new-trontinemab-long-term-data-and-preventron-phase-iii-trial-design-at-aaic-2026 2026-07-07T09:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/uk-government-issues-supply-warnings-for-nifedipine-and-oxcarbazepine-amid-multiple-brand-shortages 2026-07-07T09:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-government-issues-supply-warnings-for-nifedipine-and-oxcarbazepine-amid-multiple-brand-shortages 2026-07-07T09:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/trial-supports-glargine-use-in-resource-limited-type-1-diabetes-care-with-benefits-emerging-at-12-months 2026-07-07T04:07:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trial-supports-glargine-use-in-resource-limited-type-1-diabetes-care-with-benefits-emerging-at-12-months 2026-07-07T04:07:53+00:00 hourly 0.9 https://trial.medpath.com/news/huayuan-smartgene-secures-tens-of-millions-rmb-seed-round-to-advance-ai-powered-virtual-cell-platform-for-human-drug-efficacy-prediction 2026-07-07T03:08:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huayuan-smartgene-secures-tens-of-millions-rmb-seed-round-to-advance-ai-powered-virtual-cell-platform-for-human-drug-efficacy-prediction 2026-07-07T03:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/aureka-releases-opendde-an-open-source-ai-drug-discovery-engine-with-655m-parameters-for-antibody-antigen-co-folding 2026-07-07T03:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aureka-releases-opendde-an-open-source-ai-drug-discovery-engine-with-655m-parameters-for-antibody-antigen-co-folding 2026-07-07T03:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-unveils-eight-new-minimum-standards-to-overhaul-patient-communications-and-end-appointment-notification-failures 2026-07-07T03:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-unveils-eight-new-minimum-standards-to-overhaul-patient-communications-and-end-appointment-notification-failures 2026-07-07T03:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/from-4-to-94-survival-how-st-jude-total-therapy-clinical-trials-transformed-pediatric-all-outcomes 2026-07-07T00:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/from-4-to-94-survival-how-st-jude-total-therapy-clinical-trials-transformed-pediatric-all-outcomes 2026-07-07T00:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/amo-pharma-secures-fda-mhra-and-health-canada-alignment-on-registrational-trial-design-for-amo-02-in-congenital-myotonic-dystrophy-type-1 2026-07-06T23:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amo-pharma-secures-fda-mhra-and-health-canada-alignment-on-registrational-trial-design-for-amo-02-in-congenital-myotonic-dystrophy-type-1 2026-07-06T23:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/precision-biotics-market-poised-to-reach-17-46-billion-by-2035-driven-by-microbiome-science-and-ai-powered-discovery 2026-07-06T23:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-biotics-market-poised-to-reach-17-46-billion-by-2035-driven-by-microbiome-science-and-ai-powered-discovery 2026-07-06T23:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/wakemed-atrium-health-merger-faces-mounting-opposition-over-cost-and-charity-care-concerns 2026-07-06T22:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wakemed-atrium-health-merger-faces-mounting-opposition-over-cost-and-charity-care-concerns 2026-07-06T22:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/rxsight-announces-preliminary-q2-2026-results-alcon-collaboration-and-next-generation-light-adjustable-iol-pipeline 2026-07-06T22:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rxsight-announces-preliminary-q2-2026-results-alcon-collaboration-and-next-generation-light-adjustable-iol-pipeline 2026-07-06T22:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/radiopharmaceutical-plus-car-t-therapy-converts-immune-resistant-solid-tumors-into-treatable-targets-in-neuroblastoma-models 2026-07-06T22:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiopharmaceutical-plus-car-t-therapy-converts-immune-resistant-solid-tumors-into-treatable-targets-in-neuroblastoma-models 2026-07-06T22:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/alberta-cancer-foundation-invests-35-million-to-power-cancer-clinical-trials-across-the-province 2026-07-06T21:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alberta-cancer-foundation-invests-35-million-to-power-cancer-clinical-trials-across-the-province 2026-07-06T21:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-lenvatinib-shrinks-thyroid-tumor-and-improves-surgical-outcomes-in-advanced-thyroid-cancer 2026-07-06T20:10:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neoadjuvant-lenvatinib-shrinks-thyroid-tumor-and-improves-surgical-outcomes-in-advanced-thyroid-cancer 2026-07-06T20:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/whiddon-college-of-medicine-names-2026-dean-s-predoctoral-fellowship-awardees-for-cancer-and-infectious-disease-research 2026-07-06T20:10:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/whiddon-college-of-medicine-names-2026-dean-s-predoctoral-fellowship-awardees-for-cancer-and-infectious-disease-research 2026-07-06T20:10:12+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-researchers-identify-15-pgdh-as-promising-drug-target-for-parkinson-s-disease 2026-07-06T19:10:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-researchers-identify-15-pgdh-as-promising-drug-target-for-parkinson-s-disease 2026-07-06T19:10:30+00:00 hourly 0.9 https://trial.medpath.com/news/twelve-years-after-pharmagate-south-africa-s-patent-reform-stalemate-leaves-lifesaving-medicines-out-of-reach 2026-07-06T19:09:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/twelve-years-after-pharmagate-south-africa-s-patent-reform-stalemate-leaves-lifesaving-medicines-out-of-reach 2026-07-06T19:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/bradley-maron-named-editor-in-chief-of-circulation-bringing-precision-medicine-and-pulmonary-vascular-expertise 2026-07-06T19:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bradley-maron-named-editor-in-chief-of-circulation-bringing-precision-medicine-and-pulmonary-vascular-expertise 2026-07-06T19:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-car-like-tregs-suppress-allergic-asthma-in-mice-offering-blueprint-for-novel-allergy-immunotherapy 2026-07-06T18:11:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-car-like-tregs-suppress-allergic-asthma-in-mice-offering-blueprint-for-novel-allergy-immunotherapy 2026-07-06T18:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/drug-resistant-shigella-spreads-as-sexually-transmitted-infection-across-england-genomic-study-reveals 2026-07-06T18:10:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-resistant-shigella-spreads-as-sexually-transmitted-infection-across-england-genomic-study-reveals 2026-07-06T18:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/oncology-must-confront-hidden-side-effects-of-breakthrough-cancer-therapies 2026-07-06T18:10:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncology-must-confront-hidden-side-effects-of-breakthrough-cancer-therapies 2026-07-06T18:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-chemists-solve-30-year-rye-pollen-mystery-opening-new-avenues-for-cancer-drug-discovery 2026-07-06T18:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwestern-chemists-solve-30-year-rye-pollen-mystery-opening-new-avenues-for-cancer-drug-discovery 2026-07-06T18:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/india-selects-first-biotech-startups-under-1-trillion-r-d-initiative-as-transparency-concerns-linger 2026-07-06T17:09:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-selects-first-biotech-startups-under-1-trillion-r-d-initiative-as-transparency-concerns-linger 2026-07-06T17:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/top-10-research-priorities-published-to-shape-the-future-of-uk-childhood-food-allergy-research 2026-07-06T17:09:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/top-10-research-priorities-published-to-shape-the-future-of-uk-childhood-food-allergy-research 2026-07-06T17:09:31+00:00 hourly 0.9 https://trial.medpath.com/news/biomarker-guided-antidepressant-selection-boosts-response-rates-by-67-in-precision-psychiatry-trial 2026-07-06T17:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarker-guided-antidepressant-selection-boosts-response-rates-by-67-in-precision-psychiatry-trial 2026-07-06T17:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/transgenic-animal-model-market-poised-to-reach-6-79-billion-by-2035-driven-by-crispr-and-precision-medicine 2026-07-06T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transgenic-animal-model-market-poised-to-reach-6-79-billion-by-2035-driven-by-crispr-and-precision-medicine 2026-07-06T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/fast-walking-pace-in-80s-linked-to-50-lower-risk-of-cognitive-decline-study-finds 2026-07-06T17:08:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fast-walking-pace-in-80s-linked-to-50-lower-risk-of-cognitive-decline-study-finds 2026-07-06T17:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/disruption-of-de-novo-fatty-acid-biosynthesis-rewires-cellular-lipid-metabolism-toward-mtor-signaling 2026-07-06T17:07:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/disruption-of-de-novo-fatty-acid-biosynthesis-rewires-cellular-lipid-metabolism-toward-mtor-signaling 2026-07-06T17:07:47+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-boston-regional-biotech-hubs-attract-billions-in-manufacturing-investment 2026-07-06T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-boston-regional-biotech-hubs-attract-billions-in-manufacturing-investment 2026-07-06T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/nebius-expands-ai-discovery-awards-with-new-medical-tracks-awards-1-4-million-to-healthcare-ai-innovators 2026-07-06T16:11:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nebius-expands-ai-discovery-awards-with-new-medical-tracks-awards-1-4-million-to-healthcare-ai-innovators 2026-07-06T16:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/northwell-health-appoints-brian-s-kim-as-first-chief-biotechnology-officer-to-accelerate-bioelectronic-medicine-commercialization 2026-07-06T16:10:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwell-health-appoints-brian-s-kim-as-first-chief-biotechnology-officer-to-accelerate-bioelectronic-medicine-commercialization 2026-07-06T16:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/french-orthopedic-pioneer-movmedix-enters-u-s-market-following-fda-510-k-clearance-of-lars-r-acj-synthetic-ligament-system 2026-07-06T16:10:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/french-orthopedic-pioneer-movmedix-enters-u-s-market-following-fda-510-k-clearance-of-lars-r-acj-synthetic-ligament-system 2026-07-06T16:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/splash-beverage-group-acquires-exclusive-global-rights-to-cannepil-for-drug-resistant-epilepsy 2026-07-06T16:10:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/splash-beverage-group-acquires-exclusive-global-rights-to-cannepil-for-drug-resistant-epilepsy 2026-07-06T16:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-triples-lobbying-spend-to-1-81m-as-medicare-drug-price-negotiations-intensify 2026-07-06T16:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-triples-lobbying-spend-to-1-81m-as-medicare-drug-price-negotiations-intensify 2026-07-06T16:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/brain-organoid-research-on-the-iss-advances-toward-new-treatments-for-rett-syndrome-and-other-neurological-disorders 2026-07-06T16:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-organoid-research-on-the-iss-advances-toward-new-treatments-for-rett-syndrome-and-other-neurological-disorders 2026-07-06T16:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/persistent-disparities-in-cancer-screening-found-among-sexual-and-gender-minority-populations 2026-07-06T16:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/persistent-disparities-in-cancer-screening-found-among-sexual-and-gender-minority-populations 2026-07-06T16:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/vivos-receives-fda-ide-approval-for-first-in-human-radiogel-trial-in-non-resectable-papillary-thyroid-carcinoma 2026-07-06T15:10:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivos-receives-fda-ide-approval-for-first-in-human-radiogel-trial-in-non-resectable-papillary-thyroid-carcinoma 2026-07-06T15:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/xaira-therapeutics-expands-leadership-team-to-advance-ai-driven-drug-discovery-pipeline 2026-07-06T15:10:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xaira-therapeutics-expands-leadership-team-to-advance-ai-driven-drug-discovery-pipeline 2026-07-06T15:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-prosecutors-investigate-central-union-oil-over-carcinogen-tainted-soybean-oil-scandal 2026-07-06T15:09:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-prosecutors-investigate-central-union-oil-over-carcinogen-tainted-soybean-oil-scandal 2026-07-06T15:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/uc-san-diego-launches-institute-for-applied-health-intelligence-to-bridge-the-last-mile-of-ai-driven-care-delivery 2026-07-06T15:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-san-diego-launches-institute-for-applied-health-intelligence-to-bridge-the-last-mile-of-ai-driven-care-delivery 2026-07-06T15:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-and-summer-sun-essential-skin-safety-guidance-for-cancer-patients 2026-07-06T15:09:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-and-summer-sun-essential-skin-safety-guidance-for-cancer-patients 2026-07-06T15:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/dx-vx-advances-global-out-licensing-talks-for-first-in-class-oral-obesity-drug-and-cancer-vaccine-at-bio-2026 2026-07-06T14:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dx-vx-advances-global-out-licensing-talks-for-first-in-class-oral-obesity-drug-and-cancer-vaccine-at-bio-2026 2026-07-06T14:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/ionis-completes-enrollment-in-pivotal-cohort-of-phase-3-reveal-study-for-obudanersen-in-angelman-syndrome 2026-07-06T13:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionis-completes-enrollment-in-pivotal-cohort-of-phase-3-reveal-study-for-obudanersen-in-angelman-syndrome 2026-07-06T13:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/alzheon-to-present-new-evidence-of-neurovascular-protection-and-preserved-brain-microstructure-from-oral-valiltramiprosate-trials-in-apoe4-4-alzheimer-s-patients-at-aaic-2026 2026-07-06T13:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheon-to-present-new-evidence-of-neurovascular-protection-and-preserved-brain-microstructure-from-oral-valiltramiprosate-trials-in-apoe4-4-alzheimer-s-patients-at-aaic-2026 2026-07-06T13:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/revolver-therapeutics-secures-ps572k-to-target-undruggable-transcription-factors-in-colorectal-cancer 2026-07-06T13:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolver-therapeutics-secures-ps572k-to-target-undruggable-transcription-factors-in-colorectal-cancer 2026-07-06T13:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/domina-tablet-compression-platform-wins-the-medicine-maker-innovation-awards-2025-grand-prize 2026-07-06T13:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/domina-tablet-compression-platform-wins-the-medicine-maker-innovation-awards-2025-grand-prize 2026-07-06T13:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/biomarker-guided-antidepressant-selection-boosts-response-rates-by-nearly-67-in-precision-psychiatry-trial 2026-07-06T13:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarker-guided-antidepressant-selection-boosts-response-rates-by-nearly-67-in-precision-psychiatry-trial 2026-07-06T13:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/immuron-engages-pullan-consulting-to-secure-partner-for-imm-529-a-novel-oral-polyclonal-antibody-for-clostridioides-difficile-infection 2026-07-06T13:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuron-engages-pullan-consulting-to-secure-partner-for-imm-529-a-novel-oral-polyclonal-antibody-for-clostridioides-difficile-infection 2026-07-06T13:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/rebuilding-the-u-s-biomedical-innovation-engine-the-case-for-sustained-federal-research-investment 2026-07-06T12:08:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rebuilding-the-u-s-biomedical-innovation-engine-the-case-for-sustained-federal-research-investment 2026-07-06T12:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/pet-imaging-reveals-tau-related-brain-pattern-in-living-huntington-s-disease-patients-for-the-first-time 2026-07-06T12:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pet-imaging-reveals-tau-related-brain-pattern-in-living-huntington-s-disease-patients-for-the-first-time 2026-07-06T12:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/eight-irish-health-tech-startups-shortlisted-for-2026-kpmg-global-tech-innovator-competition 2026-07-06T11:09:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eight-irish-health-tech-startups-shortlisted-for-2026-kpmg-global-tech-innovator-competition 2026-07-06T11:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/contact-lens-import-compliance-in-2026-a-10-country-regulatory-map 2026-07-06T11:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/contact-lens-import-compliance-in-2026-a-10-country-regulatory-map 2026-07-06T11:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/lonza-upgrades-2026-margin-outlook-as-h1-performance-surges-across-all-business-platforms 2026-07-06T09:10:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lonza-upgrades-2026-margin-outlook-as-h1-performance-surges-across-all-business-platforms 2026-07-06T09:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/curifylabs-secures-eur12-million-series-a-to-expand-3d-printed-personalised-medicine-platform-across-the-u-s 2026-07-06T09:10:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curifylabs-secures-eur12-million-series-a-to-expand-3d-printed-personalised-medicine-platform-across-the-u-s 2026-07-06T09:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/teclistamab-shows-rapid-efficacy-in-two-patients-with-autoimmune-neuropathy-in-landmark-compassionate-use-report 2026-07-06T09:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teclistamab-shows-rapid-efficacy-in-two-patients-with-autoimmune-neuropathy-in-landmark-compassionate-use-report 2026-07-06T09:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/repronovo-doses-first-participant-in-eu-phase-2-nordic-trial-of-oral-oxytocin-receptor-antagonist-rpn-002-for-embryo-implantation 2026-07-06T09:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repronovo-doses-first-participant-in-eu-phase-2-nordic-trial-of-oral-oxytocin-receptor-antagonist-rpn-002-for-embryo-implantation 2026-07-06T09:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/nanomedicine-pioneer-cheon-jin-woo-named-korea-s-top-scientist-of-2026-for-magnetogenetics-and-neural-circuit-breakthroughs 2026-07-06T09:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanomedicine-pioneer-cheon-jin-woo-named-korea-s-top-scientist-of-2026-for-magnetogenetics-and-neural-circuit-breakthroughs 2026-07-06T09:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/astex-and-genentech-enter-490m-collaboration-to-target-cell-cycle-regulator-in-breast-cancer 2026-07-06T09:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astex-and-genentech-enter-490m-collaboration-to-target-cell-cycle-regulator-in-breast-cancer 2026-07-06T09:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/the-biosimilar-race-apac-s-factory-to-the-world-confronts-the-value-trap 2026-07-06T08:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-biosimilar-race-apac-s-factory-to-the-world-confronts-the-value-trap 2026-07-06T08:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-to-acquire-myricx-bio-for-up-to-1-5-billion-securing-next-generation-nmti-adc-platform-for-solid-tumours 2026-07-06T06:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-to-acquire-myricx-bio-for-up-to-1-5-billion-securing-next-generation-nmti-adc-platform-for-solid-tumours 2026-07-06T06:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/hawaii-s-first-early-phase-cancer-clinical-research-center-opens-at-uh-cancer-center 2026-07-06T04:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hawaii-s-first-early-phase-cancer-clinical-research-center-opens-at-uh-cancer-center 2026-07-06T04:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/dolly-the-sheep-at-30-how-a-cloned-ewe-paved-the-way-for-stem-cell-therapies-and-gene-edited-animals 2026-07-06T02:08:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dolly-the-sheep-at-30-how-a-cloned-ewe-paved-the-way-for-stem-cell-therapies-and-gene-edited-animals 2026-07-06T02:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/uterine-aging-may-reduce-donor-egg-pregnancy-success-after-age-49-landmark-study-finds 2026-07-06T00:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uterine-aging-may-reduce-donor-egg-pregnancy-success-after-age-49-landmark-study-finds 2026-07-06T00:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/the-dark-side-of-the-brazilian-butt-lift-boom-uk-s-underregulated-aesthetics-industry-under-scrutiny 2026-07-06T00:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-dark-side-of-the-brazilian-butt-lift-boom-uk-s-underregulated-aesthetics-industry-under-scrutiny 2026-07-06T00:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/pd-l1-pet-ct-imaging-tracks-atezolizumab-target-saturation-in-tumours-british-journal-of-cancer-study-reports 2026-07-05T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pd-l1-pet-ct-imaging-tracks-atezolizumab-target-saturation-in-tumours-british-journal-of-cancer-study-reports 2026-07-05T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/base-edited-car-t-cell-therapy-achieves-durable-remissions-in-pediatric-t-all-nejm-reports-9-of-11-patients-in-remission 2026-07-05T23:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/base-edited-car-t-cell-therapy-achieves-durable-remissions-in-pediatric-t-all-nejm-reports-9-of-11-patients-in-remission 2026-07-05T23:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/microbiota-dependent-enterocyte-oxytocin-signaling-emerges-as-a-mechanistic-link-in-autism-spectrum-disorder 2026-07-05T22:10:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microbiota-dependent-enterocyte-oxytocin-signaling-emerges-as-a-mechanistic-link-in-autism-spectrum-disorder 2026-07-05T22:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/ai-will-not-replace-doctors-but-doctors-using-ai-will-replace-those-who-don-t-says-aig-hospitals-chairman 2026-07-05T21:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-will-not-replace-doctors-but-doctors-using-ai-will-replace-those-who-don-t-says-aig-hospitals-chairman 2026-07-05T21:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/biohacker-bryan-johnson-diagnosed-with-autoimmune-gastritis-plans-experimental-treatment-approach 2026-07-05T19:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohacker-bryan-johnson-diagnosed-with-autoimmune-gastritis-plans-experimental-treatment-approach 2026-07-05T19:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/vivebiotech-and-zelluna-advance-off-the-shelf-tcr-nk-cell-therapy-for-solid-tumors-toward-2026-clinical-trials 2026-07-05T19:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivebiotech-and-zelluna-advance-off-the-shelf-tcr-nk-cell-therapy-for-solid-tumors-toward-2026-clinical-trials 2026-07-05T19:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-discover-the-deep-sleep-circuit-that-builds-muscle-burns-fat-and-boosts-the-brain 2026-07-05T18:10:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-discover-the-deep-sleep-circuit-that-builds-muscle-burns-fat-and-boosts-the-brain 2026-07-05T18:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/olean-general-hospital-reopens-renovated-mildred-milliman-radiation-medicine-center-with-4-1-million-upgrade-and-varian-truebeam-linac 2026-07-05T18:09:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olean-general-hospital-reopens-renovated-mildred-milliman-radiation-medicine-center-with-4-1-million-upgrade-and-varian-truebeam-linac 2026-07-05T18:09:47+00:00 hourly 0.9 https://trial.medpath.com/news/xelios-biometrics-advances-single-medical-record-system-using-fingerprint-identification-in-madrid-hospitals 2026-07-05T18:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xelios-biometrics-advances-single-medical-record-system-using-fingerprint-identification-in-madrid-hospitals 2026-07-05T18:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/plasma-5-hiaa-emerges-as-a-high-accuracy-biomarker-for-major-depressive-disorder 2026-07-05T17:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plasma-5-hiaa-emerges-as-a-high-accuracy-biomarker-for-major-depressive-disorder 2026-07-05T17:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/saas-adoption-in-clinical-trials-reshapes-access-compliance-and-competitive-dynamics 2026-07-05T17:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saas-adoption-in-clinical-trials-reshapes-access-compliance-and-competitive-dynamics 2026-07-05T17:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbiome-shifts-linked-to-alzheimer-s-biomarkers-before-symptoms-appear 2026-07-05T15:06:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-microbiome-shifts-linked-to-alzheimer-s-biomarkers-before-symptoms-appear 2026-07-05T15:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-escalates-etomidate-to-category-1-narcotic-as-drug-impaired-driving-cases-surge 2026-07-05T13:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-escalates-etomidate-to-category-1-narcotic-as-drug-impaired-driving-cases-surge 2026-07-05T13:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/australian-government-warns-doctors-over-ai-scribing-tools-as-privacy-and-safety-concerns-grow 2026-07-05T11:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-government-warns-doctors-over-ai-scribing-tools-as-privacy-and-safety-concerns-grow 2026-07-05T11:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/advocacy-group-urges-india-to-revise-essential-medicines-list-as-17-cancer-drugs-and-9-monoclonal-antibodies-remain-excluded 2026-07-05T07:10:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advocacy-group-urges-india-to-revise-essential-medicines-list-as-17-cancer-drugs-and-9-monoclonal-antibodies-remain-excluded 2026-07-05T07:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/indian-researchers-develop-indigenous-placenta-on-chip-platform-to-transform-pregnancy-research 2026-07-05T07:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-researchers-develop-indigenous-placenta-on-chip-platform-to-transform-pregnancy-research 2026-07-05T07:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/flavonoid-rich-foods-linked-to-15-lower-breast-cancer-risk-even-in-women-with-high-genetic-susceptibility 2026-07-05T07:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flavonoid-rich-foods-linked-to-15-lower-breast-cancer-risk-even-in-women-with-high-genetic-susceptibility 2026-07-05T07:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/analysts-maintain-bullish-stance-on-hutchmed-china-with-buy-ratings-and-price-targets-above-hk-32 2026-07-05T04:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/analysts-maintain-bullish-stance-on-hutchmed-china-with-buy-ratings-and-price-targets-above-hk-32 2026-07-05T04:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/proteogenomic-analysis-refines-medulloblastoma-into-seven-molecular-subtypes-revealing-new-therapeutic-targets 2026-07-05T04:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proteogenomic-analysis-refines-medulloblastoma-into-seven-molecular-subtypes-revealing-new-therapeutic-targets 2026-07-05T04:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/intermittent-fasting-may-offer-an-easier-path-to-weight-loss-than-calorie-counting-study-finds 2026-07-05T02:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intermittent-fasting-may-offer-an-easier-path-to-weight-loss-than-calorie-counting-study-finds 2026-07-05T02:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-secures-us-fda-approval-for-rituximab-biosimilar-fresenius-kabi-to-commercialize 2026-07-05T02:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-reddy-s-secures-us-fda-approval-for-rituximab-biosimilar-fresenius-kabi-to-commercialize 2026-07-05T02:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/ibm-ceo-quantum-computing-to-deliver-measurable-revenue-by-2028-2029-trillion-dollar-value-by-end-of-2030s 2026-07-05T00:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibm-ceo-quantum-computing-to-deliver-measurable-revenue-by-2028-2029-trillion-dollar-value-by-end-of-2030s 2026-07-05T00:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/jingze-bio-files-third-hkex-ipo-application-spotlighting-biosimilar-competition-in-china-s-fertility-and-ophthalmology-markets 2026-07-04T22:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jingze-bio-files-third-hkex-ipo-application-spotlighting-biosimilar-competition-in-china-s-fertility-and-ophthalmology-markets 2026-07-04T22:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/vagus-nerve-stimulation-produces-durable-improvements-in-severe-treatment-resistant-depression-recover-trial-shows 2026-07-04T22:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vagus-nerve-stimulation-produces-durable-improvements-in-severe-treatment-resistant-depression-recover-trial-shows 2026-07-04T22:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/morgan-stanley-upgrades-charles-river-laboratories-to-overweight-citing-biopharma-funding-rebound-and-ai-driven-discovery-tailwinds 2026-07-04T21:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/morgan-stanley-upgrades-charles-river-laboratories-to-overweight-citing-biopharma-funding-rebound-and-ai-driven-discovery-tailwinds 2026-07-04T21:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/nsw-government-imposes-tough-new-restrictions-on-nitrous-oxide-sales-to-curb-rising-abuse-and-neurological-harm 2026-07-04T21:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nsw-government-imposes-tough-new-restrictions-on-nitrous-oxide-sales-to-curb-rising-abuse-and-neurological-harm 2026-07-04T21:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/neutrophil-extracellular-traps-emerge-as-organ-specific-drivers-and-therapeutic-targets-in-ischaemia-reperfusion-injury 2026-07-04T19:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neutrophil-extracellular-traps-emerge-as-organ-specific-drivers-and-therapeutic-targets-in-ischaemia-reperfusion-injury 2026-07-04T19:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/phase-i-glutapanc-trial-l-glutamine-plus-gemcitabine-nab-paclitaxel-shows-promising-efficacy-in-advanced-pancreatic-cancer 2026-07-04T19:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-i-glutapanc-trial-l-glutamine-plus-gemcitabine-nab-paclitaxel-shows-promising-efficacy-in-advanced-pancreatic-cancer 2026-07-04T19:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/greek-cancer-patients-still-awaiting-biomarker-testing-access-eight-months-after-reform 2026-07-04T19:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greek-cancer-patients-still-awaiting-biomarker-testing-access-eight-months-after-reform 2026-07-04T19:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/xtrackers-msci-world-biotechnology-ucits-etf-shows-strong-bullish-signals-across-all-time-horizons 2026-07-04T19:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xtrackers-msci-world-biotechnology-ucits-etf-shows-strong-bullish-signals-across-all-time-horizons 2026-07-04T19:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/wave-life-sciences-advances-precision-genetic-medicines-pipeline-targeting-neurological-and-rare-diseases 2026-07-04T18:10:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wave-life-sciences-advances-precision-genetic-medicines-pipeline-targeting-neurological-and-rare-diseases 2026-07-04T18:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-fda-launches-food-safety-overhaul-after-benzopyrene-contamination-scandal-at-central-union-oil 2026-07-04T18:10:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-fda-launches-food-safety-overhaul-after-benzopyrene-contamination-scandal-at-central-union-oil 2026-07-04T18:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/florida-sues-prime-therapeutics-and-express-scripts-for-alleged-drug-price-fixing 2026-07-04T18:09:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/florida-sues-prime-therapeutics-and-express-scripts-for-alleged-drug-price-fixing 2026-07-04T18:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-call-for-global-moratorium-on-mirror-life-as-doomsday-clock-factors-in-synthetic-biology-threat 2026-07-04T18:09:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-call-for-global-moratorium-on-mirror-life-as-doomsday-clock-factors-in-synthetic-biology-threat 2026-07-04T18:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-and-apollo-hospitals-partner-to-launch-shield-multi-cancer-detection-blood-test-in-india 2026-07-04T18:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-and-apollo-hospitals-partner-to-launch-shield-multi-cancer-detection-blood-test-in-india 2026-07-04T18:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/il-6-modifies-coronary-artery-disease-risk-associated-with-elevated-lipoprotein-a-uk-biobank-study-finds 2026-07-04T18:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/il-6-modifies-coronary-artery-disease-risk-associated-with-elevated-lipoprotein-a-uk-biobank-study-finds 2026-07-04T18:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/reprogramming-macrophage-immunometabolism-via-glutamine-antagonism-potentiates-anti-tumor-immunity 2026-07-04T17:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reprogramming-macrophage-immunometabolism-via-glutamine-antagonism-potentiates-anti-tumor-immunity 2026-07-04T17:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/immunome-director-s-4-39-million-stock-sale-executed-under-pre-planned-rule-10b5-1-trading-plan-amid-pipeline-momentum 2026-07-04T17:07:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunome-director-s-4-39-million-stock-sale-executed-under-pre-planned-rule-10b5-1-trading-plan-amid-pipeline-momentum 2026-07-04T17:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/sanyou-bio-and-baiyunshan-xihe-forge-strategic-alliance-to-accelerate-ai-driven-radiopharmaceutical-development 2026-07-04T17:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanyou-bio-and-baiyunshan-xihe-forge-strategic-alliance-to-accelerate-ai-driven-radiopharmaceutical-development 2026-07-04T17:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/india-needs-national-strategy-to-bridge-gap-between-cancer-innovation-and-patient-access-experts-urge 2026-07-04T17:06:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-needs-national-strategy-to-bridge-gap-between-cancer-innovation-and-patient-access-experts-urge 2026-07-04T17:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/proton-pump-inhibitors-linked-to-reduced-durvalumab-benefit-in-stage-iii-nsclc-post-hoc-analysis-of-pacific-trial 2026-07-04T16:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proton-pump-inhibitors-linked-to-reduced-durvalumab-benefit-in-stage-iii-nsclc-post-hoc-analysis-of-pacific-trial 2026-07-04T16:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/india-calls-for-mission-mode-action-as-liver-disease-and-type-2-diabetes-surge-among-younger-populations 2026-07-04T16:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-calls-for-mission-mode-action-as-liver-disease-and-type-2-diabetes-surge-among-younger-populations 2026-07-04T16:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/global-colon-cancer-association-to-host-webinar-on-her2-positive-colorectal-cancer-and-biomarker-testing-for-patient-advocates 2026-07-04T16:07:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-colon-cancer-association-to-host-webinar-on-her2-positive-colorectal-cancer-and-biomarker-testing-for-patient-advocates 2026-07-04T16:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/oligodendrocyte-nrf2-deficiency-drives-myelin-pathology-in-age-related-cognitive-decline 2026-07-04T15:07:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oligodendrocyte-nrf2-deficiency-drives-myelin-pathology-in-age-related-cognitive-decline 2026-07-04T15:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-and-orion-corporation-partner-to-co-develop-nivolumab-biosimilar-for-european-market 2026-07-04T15:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shilpa-medicare-and-orion-corporation-partner-to-co-develop-nivolumab-biosimilar-for-european-market 2026-07-04T15:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/updated-abcs-framework-gives-clinicians-a-clearer-path-to-prevent-cardiovascular-disease 2026-07-04T14:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/updated-abcs-framework-gives-clinicians-a-clearer-path-to-prevent-cardiovascular-disease 2026-07-04T14:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/cost-efficient-long-read-trio-barcoded-adaptive-sequencing-improves-rare-disease-diagnosis 2026-07-04T14:08:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cost-efficient-long-read-trio-barcoded-adaptive-sequencing-improves-rare-disease-diagnosis 2026-07-04T14:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/guernsey-launches-island-based-cancer-trial-partnership-enabling-blood-cancer-patients-to-contribute-to-uk-research-without-travel 2026-07-04T14:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guernsey-launches-island-based-cancer-trial-partnership-enabling-blood-cancer-patients-to-contribute-to-uk-research-without-travel 2026-07-04T14:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-of-canada-affirms-methods-of-medical-treatment-are-unpatentable-upholds-janssen-s-invega-sustenna-dosing-patent 2026-07-04T10:09:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supreme-court-of-canada-affirms-methods-of-medical-treatment-are-unpatentable-upholds-janssen-s-invega-sustenna-dosing-patent 2026-07-04T10:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/lung-tumors-hijack-sensory-neurons-via-pge2-to-drive-cancer-cachexia-study-reveals 2026-07-04T05:07:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lung-tumors-hijack-sensory-neurons-via-pge2-to-drive-cancer-cachexia-study-reveals 2026-07-04T05:07:47+00:00 hourly 0.9 https://trial.medpath.com/news/research-tools-consumables-q1-earnings-waters-corporation-leads-with-91-5-revenue-growth 2026-07-04T04:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/research-tools-consumables-q1-earnings-waters-corporation-leads-with-91-5-revenue-growth 2026-07-04T04:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/invasive-fungal-infections-market-poised-for-robust-growth-by-2036-as-novel-broad-spectrum-antifungals-advance-through-pipeline 2026-07-04T02:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invasive-fungal-infections-market-poised-for-robust-growth-by-2036-as-novel-broad-spectrum-antifungals-advance-through-pipeline 2026-07-04T02:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/tenwek-hospital-recruits-consultant-specialists-and-leadership-roles-across-multiple-departments 2026-07-04T01:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenwek-hospital-recruits-consultant-specialists-and-leadership-roles-across-multiple-departments 2026-07-04T01:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/building-the-foundation-for-healthcare-ai-why-infrastructure-not-algorithms-determines-clinical-success 2026-07-04T01:06:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/building-the-foundation-for-healthcare-ai-why-infrastructure-not-algorithms-determines-clinical-success 2026-07-04T01:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/pakistan-and-china-forge-pharmaceutical-cooperation-under-cpec-2-0-at-landmark-b2b-investment-conference 2026-07-04T00:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pakistan-and-china-forge-pharmaceutical-cooperation-under-cpec-2-0-at-landmark-b2b-investment-conference 2026-07-04T00:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/family-raises-ps100000-for-dfmo-access-to-prevent-neuroblastoma-relapse-in-two-year-old-uk-girl 2026-07-04T00:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/family-raises-ps100000-for-dfmo-access-to-prevent-neuroblastoma-relapse-in-two-year-old-uk-girl 2026-07-04T00:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/organ-on-a-chip-technology-bridges-the-gap-in-patient-derived-precision-medicine 2026-07-03T23:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/organ-on-a-chip-technology-bridges-the-gap-in-patient-derived-precision-medicine 2026-07-03T23:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/sensor-based-digital-therapeutics-devices-market-to-reach-590-9-million-by-2036-driven-by-regulatory-pathways-and-payer-coverage 2026-07-03T23:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sensor-based-digital-therapeutics-devices-market-to-reach-590-9-million-by-2036-driven-by-regulatory-pathways-and-payer-coverage 2026-07-03T23:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/rituximab-market-poised-for-sustained-growth-through-2034-driven-by-multi-indication-use-and-biosimilar-expansion 2026-07-03T22:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rituximab-market-poised-for-sustained-growth-through-2034-driven-by-multi-indication-use-and-biosimilar-expansion 2026-07-03T22:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/amway-india-launches-phase-ii-of-power-of-5-school-nutrition-programme-in-new-delhi-targeting-15000-beneficiaries 2026-07-03T22:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amway-india-launches-phase-ii-of-power-of-5-school-nutrition-programme-in-new-delhi-targeting-15000-beneficiaries 2026-07-03T22:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/nk-cell-pioneer-eric-vivier-to-receive-2026-william-b-coley-award-and-deliver-inaugural-lecture-at-sitc-annual-meeting 2026-07-03T22:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nk-cell-pioneer-eric-vivier-to-receive-2026-william-b-coley-award-and-deliver-inaugural-lecture-at-sitc-annual-meeting 2026-07-03T22:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/duke-engineers-grow-retinal-blood-vessel-cells-from-ipscs-restoring-vision-in-mouse-models 2026-07-03T21:10:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duke-engineers-grow-retinal-blood-vessel-cells-from-ipscs-restoring-vision-in-mouse-models 2026-07-03T21:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-radiation-missile-radiopharmaceutical-therapy-offers-hope-to-children-with-treatment-resistant-cancers 2026-07-03T21:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-radiation-missile-radiopharmaceutical-therapy-offers-hope-to-children-with-treatment-resistant-cancers 2026-07-03T21:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/global-cosmetovigilance-market-to-reach-22-04-billion-by-2035-as-regulatory-demands-reshape-cosmetic-safety-monitoring 2026-07-03T21:09:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-cosmetovigilance-market-to-reach-22-04-billion-by-2035-as-regulatory-demands-reshape-cosmetic-safety-monitoring 2026-07-03T21:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ennumo-as-eighth-pegfilgrastim-biosimilar-expanding-oncology-supportive-care-options 2026-07-03T21:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ennumo-as-eighth-pegfilgrastim-biosimilar-expanding-oncology-supportive-care-options 2026-07-03T21:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/extreme-heat-kills-more-americans-than-hurricanes-yet-federal-disaster-law-has-never-applied 2026-07-03T20:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extreme-heat-kills-more-americans-than-hurricanes-yet-federal-disaster-law-has-never-applied 2026-07-03T20:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/ivonescimab-outperforms-keytruda-in-head-to-head-phase-iii-trial-signaling-china-s-biotech-ascent-from-the-greater-bay-area 2026-07-03T20:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ivonescimab-outperforms-keytruda-in-head-to-head-phase-iii-trial-signaling-china-s-biotech-ascent-from-the-greater-bay-area 2026-07-03T20:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/multnomah-county-replaces-deflection-center-operator-as-program-struggles-with-low-utilization 2026-07-03T20:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multnomah-county-replaces-deflection-center-operator-as-program-struggles-with-low-utilization 2026-07-03T20:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/xtalks-announces-life-science-webinar-calendar-for-july-and-august-2026-highlighting-precision-oncology-alzheimer-s-research-and-ai-driven-clinical-trials 2026-07-03T19:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xtalks-announces-life-science-webinar-calendar-for-july-and-august-2026-highlighting-precision-oncology-alzheimer-s-research-and-ai-driven-clinical-trials 2026-07-03T19:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/oncodaily-medical-journal-expands-editorial-board-with-20-oncology-specialists-across-12-countries 2026-07-03T19:08:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncodaily-medical-journal-expands-editorial-board-with-20-oncology-specialists-across-12-countries 2026-07-03T19:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-steps-up-import-enforcement-on-infant-formula-cantaloupes-and-seafood 2026-07-03T19:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-steps-up-import-enforcement-on-infant-formula-cantaloupes-and-seafood 2026-07-03T19:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/international-biotechnology-trust-declares-second-interim-dividend-of-15-67-pence-per-share 2026-07-03T18:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/international-biotechnology-trust-declares-second-interim-dividend-of-15-67-pence-per-share 2026-07-03T18:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/edding-genor-doses-first-patient-in-phase-ib-ii-trial-of-trispecific-pd-1-ctla-4-vegf-antibody-gb268-in-metastatic-breast-cancer 2026-07-03T17:11:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edding-genor-doses-first-patient-in-phase-ib-ii-trial-of-trispecific-pd-1-ctla-4-vegf-antibody-gb268-in-metastatic-breast-cancer 2026-07-03T17:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-probes-sevoflurane-linked-neurological-complications-in-patients-of-venezuelan-ancestry 2026-07-03T17:11:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-probes-sevoflurane-linked-neurological-complications-in-patients-of-venezuelan-ancestry 2026-07-03T17:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/proton-project-nominated-for-science-breakthrough-of-the-year-2026-for-novel-anti-virulence-agent-against-s-aureus 2026-07-03T17:11:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proton-project-nominated-for-science-breakthrough-of-the-year-2026-for-novel-anti-virulence-agent-against-s-aureus 2026-07-03T17:11:43+00:00 hourly 0.9 https://trial.medpath.com/news/fungal-prime-editing-platform-fpe7max-unlocks-silent-gene-clusters-yields-three-novel-anti-cancer-lead-compounds 2026-07-03T17:11:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fungal-prime-editing-platform-fpe7max-unlocks-silent-gene-clusters-yields-three-novel-anti-cancer-lead-compounds 2026-07-03T17:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/german-dairy-group-ehrmann-partners-with-glow25-to-launch-rtd-collagen-coffees 2026-07-03T17:09:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/german-dairy-group-ehrmann-partners-with-glow25-to-launch-rtd-collagen-coffees 2026-07-03T17:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/european-biotech-act-advances-as-council-agrees-negotiating-mandate-on-gmm-and-organ-processing-reforms 2026-07-03T17:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-biotech-act-advances-as-council-agrees-negotiating-mandate-on-gmm-and-organ-processing-reforms 2026-07-03T17:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/coffee-consumption-linked-to-significant-reductions-in-cirrhosis-liver-cancer-and-liver-related-death-in-large-uk-biobank-study 2026-07-03T17:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coffee-consumption-linked-to-significant-reductions-in-cirrhosis-liver-cancer-and-liver-related-death-in-large-uk-biobank-study 2026-07-03T17:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/proteinguide-a-unified-framework-for-property-guided-protein-sequence-design 2026-07-03T17:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proteinguide-a-unified-framework-for-property-guided-protein-sequence-design 2026-07-03T17:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/combined-newborn-screening-for-sma-and-scid-in-italy-achieves-100-positive-predictive-value-over-five-years 2026-07-03T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combined-newborn-screening-for-sma-and-scid-in-italy-achieves-100-positive-predictive-value-over-five-years 2026-07-03T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/wa-researchers-secure-6-1-million-to-advance-paediatric-cancer-immunotherapy-neuromuscular-disease-genetics-and-health-equity 2026-07-03T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wa-researchers-secure-6-1-million-to-advance-paediatric-cancer-immunotherapy-neuromuscular-disease-genetics-and-health-equity 2026-07-03T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/ohio-state-lands-4-million-nsf-grant-to-build-national-quantum-sensing-testbed-for-biomedical-diagnostics 2026-07-03T16:08:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ohio-state-lands-4-million-nsf-grant-to-build-national-quantum-sensing-testbed-for-biomedical-diagnostics 2026-07-03T16:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ennumotm-pegfilgrastim-pccg-accord-biopharma-s-second-pegfilgrastim-biosimilar-to-neulasta 2026-07-03T16:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ennumotm-pegfilgrastim-pccg-accord-biopharma-s-second-pegfilgrastim-biosimilar-to-neulasta 2026-07-03T16:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/dea-moves-to-classify-synthetic-7-oh-as-schedule-i-amid-rising-deaths-and-hospitalizations 2026-07-03T16:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dea-moves-to-classify-synthetic-7-oh-as-schedule-i-amid-rising-deaths-and-hospitalizations 2026-07-03T16:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/penn-medicine-launches-first-then-first-now-campaign-celebrating-275-years-of-medical-innovation 2026-07-03T16:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penn-medicine-launches-first-then-first-now-campaign-celebrating-275-years-of-medical-innovation 2026-07-03T16:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/rethinking-bladder-cancer-hidden-biology-multi-scale-networks-and-counterintuitive-therapeutic-strategies 2026-07-03T14:09:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rethinking-bladder-cancer-hidden-biology-multi-scale-networks-and-counterintuitive-therapeutic-strategies 2026-07-03T14:09:06+00:00 hourly 0.9 https://trial.medpath.com/news/harvard-s-compass-model-predicts-immunotherapy-response-across-cancers-with-concept-bottleneck-transformer 2026-07-03T13:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harvard-s-compass-model-predicts-immunotherapy-response-across-cancers-with-concept-bottleneck-transformer 2026-07-03T13:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/uk-cardiovascular-clinical-trials-market-projected-to-reach-usd-892-2-million-by-2033-driven-by-nhs-data-infrastructure-and-rising-disease-burden 2026-07-03T13:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-cardiovascular-clinical-trials-market-projected-to-reach-usd-892-2-million-by-2033-driven-by-nhs-data-infrastructure-and-rising-disease-burden 2026-07-03T13:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/multi-omics-study-reveals-proteogenomic-signature-of-high-risk-diffuse-large-b-cell-lymphoma 2026-07-03T13:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-omics-study-reveals-proteogenomic-signature-of-high-risk-diffuse-large-b-cell-lymphoma 2026-07-03T13:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/bioinnovation-institute-backs-six-startups-with-eur7-8m-to-bridge-europe-s-translational-gap 2026-07-03T13:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioinnovation-institute-backs-six-startups-with-eur7-8m-to-bridge-europe-s-translational-gap 2026-07-03T13:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-microenvironment-modulation-market-projected-to-reach-usd-3-73-billion-by-2031-growing-at-7-4-cagr 2026-07-03T10:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-microenvironment-modulation-market-projected-to-reach-usd-3-73-billion-by-2031-growing-at-7-4-cagr 2026-07-03T10:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/biomaterial-based-strategies-reshape-gout-therapy-from-nanoparticles-to-microneedles 2026-07-03T10:09:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomaterial-based-strategies-reshape-gout-therapy-from-nanoparticles-to-microneedles 2026-07-03T10:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/global-antidiabetic-drugs-market-projected-to-reach-usd-309-84-billion-by-2035-driven-by-glp-1-and-sglt2-innovation 2026-07-03T10:09:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-antidiabetic-drugs-market-projected-to-reach-usd-309-84-billion-by-2035-driven-by-glp-1-and-sglt2-innovation 2026-07-03T10:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/global-trop-2-targeted-therapy-market-projected-to-reach-3-29-billion-by-2031-driven-by-adc-innovation-and-rising-cancer-prevalence 2026-07-03T10:09:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-trop-2-targeted-therapy-market-projected-to-reach-3-29-billion-by-2031-driven-by-adc-innovation-and-rising-cancer-prevalence 2026-07-03T10:09:31+00:00 hourly 0.9 https://trial.medpath.com/news/sky-labs-unveils-ring-type-cuffless-blood-pressure-monitor-cart-bp-pro-for-drug-clinical-trials-at-basel-summit 2026-07-03T10:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sky-labs-unveils-ring-type-cuffless-blood-pressure-monitor-cart-bp-pro-for-drug-clinical-trials-at-basel-summit 2026-07-03T10:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/global-microbiome-oncology-market-projected-to-reach-1-94-billion-by-2031-growing-at-40-7-cagr 2026-07-03T10:09:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-microbiome-oncology-market-projected-to-reach-1-94-billion-by-2031-growing-at-40-7-cagr 2026-07-03T10:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/global-cancer-biologics-market-projected-to-reach-189-billion-by-2035-driven-by-antibody-dominance-and-precision-medicine 2026-07-03T09:09:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-cancer-biologics-market-projected-to-reach-189-billion-by-2035-driven-by-antibody-dominance-and-precision-medicine 2026-07-03T09:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/gene-editing-therapeutics-market-poised-for-12-5-cagr-growth-driven-by-crispr-dominance-and-oncology-applications 2026-07-03T09:09:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-editing-therapeutics-market-poised-for-12-5-cagr-growth-driven-by-crispr-dominance-and-oncology-applications 2026-07-03T09:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/uq-researchers-develop-first-drug-targeting-elusive-c5ar2-receptor-paving-path-to-transform-mnd-into-a-manageable-chronic-condition 2026-07-03T09:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uq-researchers-develop-first-drug-targeting-elusive-c5ar2-receptor-paving-path-to-transform-mnd-into-a-manageable-chronic-condition 2026-07-03T09:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/the-vein-to-vein-problem-can-apac-s-cold-chain-carry-advanced-therapies 2026-07-03T09:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-vein-to-vein-problem-can-apac-s-cold-chain-carry-advanced-therapies 2026-07-03T09:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/symeres-and-axxam-appoint-russell-thomas-as-joint-cso-to-unify-integrated-drug-discovery-platform 2026-07-03T08:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/symeres-and-axxam-appoint-russell-thomas-as-joint-cso-to-unify-integrated-drug-discovery-platform 2026-07-03T08:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/alibaba-to-pay-600-million-to-settle-doj-probe-into-illegal-pharmaceutical-sales-on-its-platforms 2026-07-03T07:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alibaba-to-pay-600-million-to-settle-doj-probe-into-illegal-pharmaceutical-sales-on-its-platforms 2026-07-03T07:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/new-early-phase-cancer-clinical-trials-unit-opens-at-royal-north-shore-hospital-in-sydney 2026-07-03T07:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-early-phase-cancer-clinical-trials-unit-opens-at-royal-north-shore-hospital-in-sydney 2026-07-03T07:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-ai-integration-faces-leadership-uncertainty-after-high-level-departures 2026-07-03T05:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-ai-integration-faces-leadership-uncertainty-after-high-level-departures 2026-07-03T05:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/asbmb-names-five-recipients-of-2026-science-outreach-and-communication-grants 2026-07-03T05:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asbmb-names-five-recipients-of-2026-science-outreach-and-communication-grants 2026-07-03T05:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-panel-rejects-abbvie-s-clinical-trial-waiver-for-parkinson-s-drug-mandates-phase-iii-study-in-india 2026-07-03T04:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-panel-rejects-abbvie-s-clinical-trial-waiver-for-parkinson-s-drug-mandates-phase-iii-study-in-india 2026-07-03T04:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/agilent-launches-ai-powered-xcelligence-rtca-esight-ai-module-for-label-free-live-cell-imaging-analysis 2026-07-03T04:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agilent-launches-ai-powered-xcelligence-rtca-esight-ai-module-for-label-free-live-cell-imaging-analysis 2026-07-03T04:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-casgevy-approval-to-children-ages-2-nashville-hospital-treats-first-commercial-patient 2026-07-03T04:07:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-casgevy-approval-to-children-ages-2-nashville-hospital-treats-first-commercial-patient 2026-07-03T04:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/gravity-activates-mitochondrial-translation-space-station-study-reveals-molecular-pathway-linking-mechanical-forces-to-cellular-energy-production 2026-07-03T02:12:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gravity-activates-mitochondrial-translation-space-station-study-reveals-molecular-pathway-linking-mechanical-forces-to-cellular-energy-production 2026-07-03T02:12:06+00:00 hourly 0.9 https://trial.medpath.com/news/ai-designed-wrap-proteins-solve-decades-old-membrane-protein-solubility-problem-opening-door-to-syphilis-vaccine 2026-07-03T02:11:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-designed-wrap-proteins-solve-decades-old-membrane-protein-solubility-problem-opening-door-to-syphilis-vaccine 2026-07-03T02:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/rentschler-biopharma-appoints-former-bachem-cco-torsten-wohr-as-ceo-to-lead-next-growth-phase 2026-07-03T02:11:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rentschler-biopharma-appoints-former-bachem-cco-torsten-wohr-as-ceo-to-lead-next-growth-phase 2026-07-03T02:11:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-zyn-nicotine-pouches-to-carry-modified-risk-claim-as-safer-alternative-to-cigarettes 2026-07-03T02:11:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-authorizes-zyn-nicotine-pouches-to-carry-modified-risk-claim-as-safer-alternative-to-cigarettes 2026-07-03T02:11:11+00:00 hourly 0.9 https://trial.medpath.com/news/advances-in-targeting-il-1-family-cytokines-for-inflammatory-disease-treatment 2026-07-03T02:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advances-in-targeting-il-1-family-cytokines-for-inflammatory-disease-treatment 2026-07-03T02:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/norovirus-outbreak-on-ruby-princess-sickens-125-during-alaska-cruise-from-san-francisco 2026-07-02T23:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/norovirus-outbreak-on-ruby-princess-sickens-125-during-alaska-cruise-from-san-francisco 2026-07-02T23:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/bcg-immunotherapy-reprograms-cns-immunity-and-alters-amyloid-dynamics-in-older-adults 2026-07-02T23:09:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bcg-immunotherapy-reprograms-cns-immunity-and-alters-amyloid-dynamics-in-older-adults 2026-07-02T23:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/federal-youth-online-safety-bills-advance-raising-compliance-challenges-for-cannabis-advertising 2026-07-02T22:09:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-youth-online-safety-bills-advance-raising-compliance-challenges-for-cannabis-advertising 2026-07-02T22:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/x-cell-derived-antibody-shows-potential-to-reverse-type-1-diabetes-in-preclinical-models 2026-07-02T22:09:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/x-cell-derived-antibody-shows-potential-to-reverse-type-1-diabetes-in-preclinical-models 2026-07-02T22:09:44+00:00 hourly 0.9 https://trial.medpath.com/news/vivani-medical-to-spin-out-neurostimulation-subsidiary-cortigent-via-merger-with-nasdaq-listed-clearone 2026-07-02T21:12:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivani-medical-to-spin-out-neurostimulation-subsidiary-cortigent-via-merger-with-nasdaq-listed-clearone 2026-07-02T21:12:18+00:00 hourly 0.9 https://trial.medpath.com/news/single-cell-proteomics-reveals-hidden-cardiomyocyte-diversity-reshaping-precision-medicine-and-drug-development 2026-07-02T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-cell-proteomics-reveals-hidden-cardiomyocyte-diversity-reshaping-precision-medicine-and-drug-development 2026-07-02T21:11:31+00:00 hourly 0.9